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a b s t r a c t
Understanding the pathophysiogenesis of temporal lobe epilepsy (TLE) largely rests on the use of models
of status epilepticus (SE), as in the case of the pilocarpine model. The main features of TLE are: (i) epileptic
foci in the limbic system; (ii) an “initial precipitating injury”; (iii) the so-called “latent period”; and (iv)
the presence of hippocampal sclerosis leading to reorganization of neuronal networks. Many of these
characteristics can be reproduced in rodents by systemic injection of pilocarpine; in this animalmodel, SE
is followed by a latent period and later by the appearance of spontaneous recurrent seizures (SRSs). These
processes are, however, inﬂuenced by experimental conditions such as rodent species, strain, gender, age,
doses and routes of pilocarpine administration, as well as combinations with other drugs administered
before and/or after SE. In the attempt to limit these sources of variability,we evaluated themethodological
procedures used by several investigators in the pilocarpine model; in particular, we have focused on the
behavioural, electrophysiological and histopathological ﬁndings obtained with different protocols. We
addressed the various experimental approaches published to date, by comparingmortality rates, onset of
SRSs, neuronal damage, and ne
that the pilocarpinemodel can
more so when standardized to
period duration, variability in t
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2. Behavioural, electrophysiological and histological features . . . . . . . . . . . . . . .
2.1. Status epilepticus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.2. Latent period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.3. Chronic period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.3.1. Chronic limbic seizures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.3.2. Seizure-induced damage and network reorganization. . .
3. Pilocarpine doses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4. Routes of administration of pilocarpine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5. Duration of status epilepticus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6. The lithium–pilocarpine model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7. Pilocarpine in combination with other drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: AEDs, antiepileptic drugs; CA, Cornu Ammonis; EEG, electroencephalo
P, postnatal; s.c., subcutaneous; SE, status epilepticus; SRSs, spontaneous recurrent seizure
∗ Corresponding author at: 3801 University, Room 794, Montreal, QC, Canada H3A 2B4.
E-mail address: massimo.avoli@mcgill.ca (M. Avoli).
0165-0270 © 2008 Elsevier B.V.
doi:10.1016/j.jneumeth.2008.04.019
Open access under CC BY license.twork reorganization. Based on the evidence reviewed here, we propose
be a valuable tool to investigate themechanisms involved in TLE, and even
reduce mortality at the time of pilocarpine injection, differences in latent
he lesion extent, and SRS frequency.
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1. Introduction
The ability to reproduce human diseases in animal models
presents a great advantage for modern experimental medicine
(Russell, 1964). The ideal animal model is homologous, duplicat-
ing the human disorder in every respect. Alternatively, the animal
model could be isomorphic, when it duplicates the disorder but
not the underlying aetiology (that in many neurological diseases is
unknown), or predictive, in the case in which it does not resemble
the human disorder but allows predictions about it or its response
to treatment (this is the case of the kindling paradigm for epilepsy).
A great deal of the knowledge that has improved our understanding
of epileptic disorders has derived from appropriate animal models
(Purpura et al., 1972; Schwartzkroin, 1983; Pitka¨nen et al., 2006).
This is certainly the case in temporal lobe epilepsy (TLE), the most
common type of partial complex seizure in adulthood (Hauser et
al., 1996; Wieser, 2004).
The main features of TLE are: (i) the localization of seizure foci
in the limbic system, particularly in the hippocampus, entorhinal
cortex andamygdala (Bartolomei et al., 2005); (ii) the frequentﬁnd-
ing of an “initial precipitating injury” that precedes the appearance
of TLE (Mathern et al., 2002); (iii) a seizure-free time interval fol-
lowing the precipitating injury known as “latent period”; and (iv)
a high incidence of mesial or Cornu Ammonis (CA) sclerosis, i.e., a
unilateral hippocampal lesion leading to atrophy, typically caused
byneuronal loss andgliosis in Sommer’s sector (the subiculum-CA1
transition zone) and the endfolium (dentate hilus) (Mathern et al.,
1997b).
Most of these characteristics can be reproduced in chronic ani-
mal models of TLE, particularly kindling or status epilepticus (SE)
animal models, which come close to being the ideal homologous
modelmentioned above (Morimoto et al., 2004). The subject of this
review, the pilocarpine model, belongs to SE models. This model
appears to be highly isomorphic with the human disease, so it has
been used in many laboratories since its ﬁrst description a quarter
of a century ago (Turski et al., 1983a,b). Histopathological ﬁndings
(Covolan and Mello, 2000) in the pilocarpine model and its use in
studying the efﬁcacy of antiepileptic drugs (AEDs; Leite et al., 2002)
have been reviewed recently. In this paper we will therefore focus
on methodological procedures and the behavioural consequences,
especially in view of recent advances in this ﬁeld made possible by
an increasing use of video-electroencephalography (EEG) record-
ings.
Some important features of the pilocarpine model are: (i) the
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kainic acid, the other convulsant drug commonly used to repro-
duce TLE in animals; (ii) the presence of a latent period followed
by the appearance of spontaneous recurrent seizures (SRSs, chronic
phase) (Leite et al., 1990;Cavalheiro et al., 1991); (iii) theoccurrence
of widespread lesions (see Section 2.3.2), some of them localized in
the same brain areas affected in TLE patients, and associated with
neuronal network reorganization in hippocampal and parahip-
pocampal regions (for instance, mossy ﬁbre sprouting, interneuron
loss and ectopic dentate granule cell proliferation are phenomena
shared by TLE patients and pilocarpine-treated animals; Wieser,
2004); (iv) the fact that seizures are poorly controlled by AEDs
in patients and pilocarpine-treated epileptic rodents (Glien et al.,
2002; Chakir et al., 2006).
The ability of pilocarpine to induce SE is likely to depend
on activation of the M1 muscarinic receptor subtype, since M1
receptor knockout mice do not develop seizures in response to
pilocarpine (Hamilton et al., 1997). Other cholinomimetics, such
as carbachol and oxotremorine, are also able to induce seizures and
seizure-induced brain damage when injected either systemically
or directly into the brain (Olney et al., 1983; Turski et al., 1983b).
In addition, pilocarpine-induced SE can be blocked by systemic
administration of the muscarinic antagonist atropine (Clifford et
al., 1987). Once seizures are initiated, however, their maintenance
depends on other mechanisms since atropine becomes ineffec-
tive (Clifford et al., 1987). Experiments in cultured hippocampal
neurons have demonstrated that pilocarpine, acting through mus-
carinic receptors, causes an imbalance between excitatory and
inhibitory transmission resulting in the generation of SE (Priel and
Albuquerque, 2002). In addition, in vivo microdialysis studies have
revealed thatpilocarpine inducesanelevation inglutamate levels in
thehippocampus following theappearanceof seizures (Smolders et
al., 1997). Substantial evidence now supports the suggestion that,
following initiation by M1 receptors, seizures are maintained by
NMDAreceptor activation (Nagaoet al., 1996; Smolders et al., 1997).
The pilocarpinemodel is nowwidely used and it has beenmod-
iﬁed in a number of laboratories. Depending on the aims of the
experiments, different groups of researchers use different dosages
of pilocarpine, pretreatment procedures, animal strain and species.
In addition, the duration of SE induced by pilocarpine or the drugs
employed to terminate it are often inconsistent. Thesemultifaceted
protocols could well contribute to the variable ﬁndings obtained in
different studies. Indeed, the lack of a standardized approach to the
pilocarpine model could play a critical role in how it recreates the
human scenario. These aspects have recently led some investiga-
tors to criticize the pilocarpine model and to propose alternative
scienc
e lithi
using
n, res
imental purposes (Glien et al., 2001). As an alternative approach
to reducing mortality, many groups have limited SE duration using
diazepam. Indeed, reduction of the SE length does result in a signif-
icant decrease in mortality rate (Fig. 1). However, it must be noted
that SE duration is crucial for the development of the full syndrome
(see below).
EEG activity. EEG recordings during SE immediately after injec-
tion have shown that pilocarpine can evoke both ictal and interictal
epileptic events as well as that these EEG patterns are correlated
with behavioural changes. As shown in Fig. 2, low voltage, fast
activity ﬁrst appears in neocortex and amygdala, while a clear pat-
tern of theta rhythm is evident in the hippocampus. When the
behavioural manifestations become more severe, high voltage, fast
EEG activity replaces the hippocampal theta rhythm. Moreover, at
later stages, animals develop electrographic seizures, characterized
by high voltage, fast activity and prominent high voltage spiking
that precedes seizures, most likely due to muscarinic system acti-
vation (Fisahn et al., 1998; Van der Linden et al., 1999). This activity
appears to originate in the hippocampus and to propagate to the
amygdala and neocortex (Turski et al., 1983a).G. Curia et al. / Journal of Neuro
Table 1
Mortality rates found in different laboratories by investigating the pilocarpine or th
Pilocarpine dose (mg/kg) SE duration (min)
320–360 90
120
>120
380 >120
>120
>120
30 (lithium pretreatment, 3mEq/kg) 90
>120
>120
Note the wide variability found in the different experimental sessions even when
variables difﬁcult to be controlled could inﬂuence the animal response to SE inductio
as the lowest mortality rates have been observed in Sprague–Dawley rats.
a Wistar rats (mortality rate: 54.00±27.25).
b Sprague–Dawley rats (mortality rate: 19.25±11.09).
approaches to reproduce TLE in animals (Sloviter, 2005; Sloviter et
al., 2007). In this review we will compare the different protocols
used in the pilocarpine model, and in particular to gain consensus
as towhat factorsmay be critical inwhat is perhaps one of themost
appropriate models of TLE.
2. Behavioural, electrophysiological and histological
features
Injection of pilocarpine induces a SE that is characterized
by tonic–clonic generalized seizures. After several hours of SE,
pilocarpine-treated animals remit spontaneously and go into a
seizure-free period, known as latent period, before displaying the
SRSs that characterize the chronic epileptic condition.
2.1. Status epilepticus
Behaviour. The pilocarpine model was developed by Turski’s
group (1983a,b). These initial studies provided a qualitative but
extensive description of the behavioural, electroencephalographic
and histopathological consequences of SE induction by pilocarpine.
In these experiments, pilocarpine (400mg/kg, i.p.) was injected in
adultmaleWistar rats, and a progressive evolution of seizures, sim-
ilar to that classiﬁed by Racine (1972) in the kindling model, was
observed.
According to Turski et al. (1983a), animals were motionless for
5–10min after pilocarpine administration and subsequently dis-
played oro-facial movements, salivation, eye-blinking, twitching of
vibrissae, and yawning. This activity persisted up to 45min. Then,
discontinuous seizures were observed 30min after injection and
lasted up to 90–150min, before givingway to limbicmotor seizures
with intense salivation, rearing, upper extremity clonus, and falling.
Such seizures were observed every 5–15min, presenting maximal
frequency after 1–2h. After pilocarpine injection, around60%of the
rats successfully developed SE (Cavalheiro et al., 1991). SE sponta-
neously remitted 5–6h after pilocarpine administration, and the
animals entered post-ictal coma, lasting 1–2 days. Body weight
decreased after SE (10–20%), but recovered to pretreatment values
after approximately 1 week (Turski et al., 1989).
Mortality rates at the time of the injection have been reported to
bearound30–40% formaleWistar rats treatedwith300–400mg/kg
pilocarpine; this is a range of doses that is able to reproduce the
completepilocarpine-induced syndrome (Turski et al., 1983a, 1989;
Cavalheiroet al., 1991; Liuet al., 1994b).However, other laboratories
have found even worse outcomes (Table 1). In an attempt to ame-
liorate such a high mortality rate, some researchers have divided
the pilocarpine treatments, injecting an initial dose of 200mg/kg,e Methods 172 (2008) 143–157 145
um–pilocarpine models
Mortality (%) Mortality mean± S.D. References
17b Williams et al. (2002)
55a 37.3 ± 19.1 Esclapez et al. (1999)
40a Gofﬁn et al. (2007)
5b Poirier et al. (2000)
30a 22.0 ± 14.7 Leite et al. (1990)
31b Liu et al. (1994b)
45a Fujikawa et al. (1999)
24b 56.0 ± 39.2 Glien et al. (2001)
100a Fujikawa et al. (1999)
similar experimental protocols. These discrepancies suggest that environmental
ulting in a different survival probability. The rat strain also appears to be important,
and then additional 100mg/kg doses until induction of SE (Glien et
al., 2001). This repeated administration of low-doses signiﬁcantly
decreased mortality, but even this approach was unsatisfactory as
the average delay from the ﬁrst injection of pilocarpine to the onset
of SE could amount up to 360min, somehow impractical for exper-Fig. 1. Histogram showing the changes in mortality as function of status epilepticus
(SE) duration. Values represent the means of three to four different experiments
(n=15–20 rats for the different time intervals) in which seizures were quelled by
injecting diazepam (20mg/kg, i.p.) 30, 60, 120 or 180min after pilocarpine-induced
SE. Pilocarpine was used at 380mg/kg after a scopolamine methylnitrate injection
(1mg/kg, 30min before pilocarpine) in Sprague–Dawley rats at 8 weeks of age (cf.
Biagini et al., 2006, 2008). Note that a 180-min SE causes a signiﬁcantly (p<0.05)
higher mortality when compared with all the other time intervals (analysis of vari-
ance followed by Games–Howell test for multiple comparisons).
146 G. Curia et al. / Journal of Neuroscienc
lyzed Wistar rats with a body weight range of 285–350g that was
similar to that of the Sprague–Dawley rats (270–300g) used by
Biagini et al. (2006). Thus, the differences found by these authors
are not explained by the rat strain or age. In contrast, a possible fac-
tor of variance is the pharmacological approach to abort SE, since
the animals developing SRSs more rapidly were treated only with
diazepam (20mg/kg, i.p.) (Biagini et al., 2006; Gofﬁn et al., 2007).
Apart from occasional rats that continue to present seizures in
the ﬁrst 3 days after SE (Cavalheiro et al., 1991), pilocarpine-treated
animals generally show normal behaviour and EEG activity during
the latent period. It is, however, believed that during the latent
period several pathophysiological phenomena that are related
to epileptogenesis may occur. These events include mossy ﬁbre
sprouting, interneuron loss, rewiring of synaptic circuits, glial cell
activation, and ectopic cell proliferation (Dalby and Mody, 2001;
Pitka¨nen and Sutula, 2002). As there is no deﬁnitive evidence that
any of these phenomena is critical for epileptogenesis, it will be
important to evaluate in future studies how they vary in relation-
ship to SE duration and the consequent alterations in the latent
period extension. For instance, we have recently shown a directFig. 2. EEG recordings obtained after pilocarpine (400mg/kg, i.p.) administration.
Note that 5min after injection, low voltage fast activity appears in amygdala (Amy)
and neocortex (Ctx), while theta rhythm is evident in the hippocampus (Hippo).
Twenty minutes after, high-voltage fast activity is seen in amygdala and neocor-
tex, while spikes superpose in the hippocampus. In the 30min traces, high voltage
spikes are detected ﬁrst in the hippocampuswhile at 40min, high voltage spikes are
recorded from all the ﬁelds. After 50min from the injection, electrographic seizures
are seen and followed by post-ictal depression (60min sample). At 120min, the EEG
corresponds to status epilepticus (modiﬁed from Turski et al., 1983a).
As illustrated in the EEG sample obtained 60min after pilo-
carpine injection, the ictal discharges are followed by depression of
the EEG activity. By 1–2h after pilocarpine treatment, the electro-
graphicactivityprogresses toaSE that lasts5–6h, and is followedby
gradual normalization of the EEG over several hours.When the ani-
mals recover from SE and post-ictal coma (approximately 24–48h
after), the EEG is considered normal although a theta rhythm that
is weaker than before pilocarpine treatment can be recorded in the
hippocampus (Turski et al., 1983a).
2.2. Latent period
The duration of the latent (also termed silent or quiescent)
period differs depending on the protocol used. In Wistar rats
injected with pilocarpine (380mg/kg), it lasts from 1 up to 6weeks
with a mean time interval of 14.8 days (Cavalheiro et al., 1991).
Varying the pilocarpine dose from 350 up to 400mg/kg induces
only slight differences in the time of onset of SRSs (Liu et al., 1994b).e Methods 172 (2008) 143–157
In contrast, when the duration of SE is varied by arresting seizures
with diazepam alone or combinedwith other drugs, such as pento-
barbital or phenytoin (Lemos andCavalheiro, 1995; Fujikawa, 1996;
Biagini et al., 2006), the latent periodduration changes signiﬁcantly
as a function of the different time intervals of continuous seizure
activity in the acute period.
According to Lemos and Cavalheiro (1995), rats undergoing 30-
min long SE and treated with a single (i.p.) injection of diazepam
(10mg/kg) and pentobarbital (30mg/kg) do not develop SRSs. In
contrast, animals presenting with SE lasting 1, 2, 6 or several hours
exhibit latent periods of 52, 38, 17 and 14 days, respectively. How-
ever, we have been unable to conﬁrm these data since we found
that the latent period is progressively shortened by decreasing the
SE length (Fig. 3) (Biagini et al., 2006). It should also be noted that a
recent studybasedon continuous video-EEG recordings, has shown
a mean latent period of approximately 7 days after a 2h SE (Gofﬁn
et al., 2007). In these studies, Lemos and Cavalheiro (1995) used
Wistar rats weighing 200–250g, whereas Gofﬁn et al. (2007) ana-Fig. 3. Kaplan–Meier analysis of the time of spontaneous seizure appearance after
status epilepticus (SE) induced by injecting Sprague–Dawley rats with pilocarpine
(380mg/kg, i.p.) after a scopolaminemethylnitrate injection (1mg/kg, 30minbefore
pilocarpine). Note that the spontaneous seizure onset is progressively delayed by
increasing SE duration (seizures were quelled by injecting 20mg/kg diazepam at
different time intervals from the pilocarpine injection, cf. Biagini et al., 2006). The
log rank test revealed a signiﬁcant (**p<0.01) difference between the 180-min SE
group and the others (n=9–14/group).
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relationbetween the latentperioddurationand theextentof induc-
tion in glial cells of the rate-limiting enzyme of the neurosteroid
pathway, the cholesterol side-chain cleavage enzyme coupled to
the cytochrome P450 (P450scc) (Biagini et al., 2006). Neurosteroids
such as allopregnanolone are anticonvulsants that are mainly syn-
thesized in astrocytes; these glial cells are highly activated by
seizures and brain damage. Interestingly, we have found that a
longer SE corresponds to a larger hippocampal lesion and thus a
stronger activation of glial cells that ﬁnally might be able to extend
the latent period by synthesizing seizure-modulating substances
like neurosteroids (Biagini et al., 2006, 2008).
2.3. Chronic period
The chronic period follows epileptogenesis and is characterized
by the appearance of SRSs. As with the latent or silent phase, dis-
crepancies in the characteristics of the chronic period emerge from
studies made in different laboratories with the pilocarpine model.
We will therefore discuss these discrepancies by considering ﬁrst
the data regarding the seizure characteristics, and then those con-
cerning the neuronal damage that occurs in the brain of these
animals.
2.3.1. Chronic limbic seizures
Behaviour. SRSs, which appear in pilocarpine-treated rats after
the latent period, have recently been reclassiﬁed by Veliskova
(2006) according to the following criteria: 1, staring and mouth
clonus; 2, automatisms; 3, monolateral forelimb clonus; 4, bilat-
eral forelimb clonus; 5, bilateral forelimb clonus with rearing and
falling; 6, tonic-clonic seizure. As proposed by Gofﬁn et al. (2007),
this classiﬁcation could be simpliﬁed by referring to criteria 1–3
as partial seizures, and 4–6 as secondarily generalized seizures.
According to this classiﬁcation, SRSs begin approximately 7 days
after SE as partial seizures, becoming generalized seizures in the
following days (Gofﬁn et al., 2007). Arida et al. (1999) performed
a careful analysis of SRSs in adult male Wistar rats injected with
350mg/kg pilocarpine, and found a relationship between the rate
of occurrence of seizures and the duration of the latent period.
They detected the ﬁrst spontaneous seizure between 3 and 30 days
after pilocarpine injection. Shorter latent periods (3–5 days) were
found inanimals that eventually experiencedmore (124–727)SRSs;
longer latent periods (28–30 days) were related to lower number
of SRSs (range 45–584) during 135 days of observation.
An additional feature of SRSs is that, once manifested, they
appear to recur in a clustered way in a cycle peaking every 5–8
days (Gofﬁn et al., 2007) or more (Arida et al., 1999). Besides these
observations, SRSs appear to be relatively regular throughout the
lifetime of the animal (Priel et al., 1996). It should also be empha-
sized that seizure frequencyhas been found to vary according to the
method used tomonitor the animals (visual inspection, videomon-
itoring or continuous video-EEG recording) and the type of seizures
scored (partial or generalized). Originally, in adult maleWistar rats
given300–320mg/kgofpilocarpine, amean latentperiodof14days
and a frequency of 2.8 seizures per week were found by continu-
ously video monitoring (Cavalheiro et al., 1991, 1996; Lemos and
Cavalheiro, 1995; Arida et al., 1999). Seizure frequency was higher
during the diurnal period (from 7:00a.m. to 7:00p.m.) when the
animalswerekept in a12-hdark/light cycle (Arida et al., 1999). Sim-
ilarly, video-EEG recordings have established that approximately
67%ofdaily seizuresoccurduring the lightphaseof the cycle (Gofﬁn
et al., 2007). Arida et al. (1999) have also reported that animals pre-
senting with a low SRS occurrence (mean=8) during the ﬁrst 15
days, reach a peak (75 SRSs) at day 76. Then, they decrease to 61
at day 105 and do not display any signiﬁcant change between days
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(n=29) during the ﬁrst 15 days, reach a peak (51 SRSs) at day 60
and do not change signiﬁcantly between days 75 and 135.
EEG activity. SRSs in pilocarpine-treated animals are character-
ized by bursts of spiking activity in the hippocampus that spread
to the neocortex in 90% of the cases (Cavalheiro et al., 1991). Elec-
trographic seizures rarely last more than 60 s and are followed by
depressed background activity with frequent EEG interictal spikes.
Bursts of spiking activity are not observed in the neocortex alone
(Cavalheiro et al., 1991). In addition, interictal activity is more
intense when animals are seizure-free and during the sleep period
while they are almost undetectable duringmotor activity and para-
doxical sleep (Arida et al., 1999).
2.3.2. Seizure-induced damage and network reorganization
Animals experiencing SE for several hours (i.e. not terminated
byanypharmacological intervention) showhistopathological alter-
ations that are localized within the olfactory cortex, amygdala,
thalamus, hippocampal formation, and neocortex. Several areas
appear swollen and edematous and many cells are dark and
shrunken (Turski et al., 1983a). Some areas such as the lateral tha-
lamic nucleus, substantia nigra and dentate hilus are damaged only
in animals that develop chronic SRSs (Priel et al., 1996). However,
other authors have found that hilar mossy cells can survive SE and
be subsequently activated by SRSs (Scharfman et al., 2001). Cell loss
(Fig. 4) has been detected in the subiculum (Knopp et al., 2005; de
Guzman et al., 2006), amygdala (Turski et al., 1983a) and layer III
of themedial entorhinal cortex (Du et al., 1995; Biagini et al., 2005;
Wozny et al., 2005). In addition, injured neurons, mainly interneu-
rons, can be found in the hippocampus (CA1 and CA3 stratum
pyramidale and radiatum), amygdala and piriform cortex (Mello
and Covolan, 1996).
It has been reported that superﬁcial layers of the sensorimotor
cortex are particularly affected with marked atrophy and dendritic
sprouting, suggesting lesion, reorganization and neuroplasticity of
neocortical networks (Sanabria et al., 2002). The thickness of neo-
cortex is indeed reduced in pilocarpine-treated animals compared
to controls. In addition, the laminar cortical organization is dis-
rupted, and a lowerneuronal density is evident in epileptic animals.
Reactive gliosis is also observed in the superﬁcial third of the cortex
of epileptic animals (Silva et al., 2002).
Network reorganization in pilocarpine-treated animals occurs
presumably as consequence of neuronal loss and SE-induced
sprouting (Lehmann et al., 2001). SE also appears to induce for-
mation of ectopic cells that are recruited into the nascent network
(Scharfman et al., 2003). Neocortical neurons with a dense arbori-
sation of apical dendrites in themost superﬁcial layers are apparent
in rats with SRSs (Silva et al., 2002). At variance, the presence
of subicular neurons with a reduced arborisation and spine den-
sity in the proximal part of the apical dendrites suggests a partial
deafferentiation from CA1 (Knopp et al., 2005). It is still debated
whether and how such changes participate in the initiation of SRSs,
and how they lead to chronic epilepsy. Indeed, studies by Mello
and collaborators (Longo and Mello, 1997; Dos Santos et al., 2000;
Longo et al., 2002) have shown that cycloheximide administered to
pilocarpine-treated rats to block protein synthesis, and thusmossy
ﬁbre sprouting, causes little change in latent period duration and
no consequences for the establishment of a chronic epileptic con-
dition. However, these ﬁndings have been questioned by another
study in which cycloheximide treatment failed to reduce mossy
ﬁbre sprouting (Williams et al., 2002).
The contribution of neuronal damage to the development of
SRSs is also unclear. It is well known that mossy ﬁbre sprouting
can be observed without neuronal damage (i.e., in the kindling
model; cf. Morimoto et al., 2004) and that electroconvulsive shock
seizure repeated for several days induces mossy ﬁbre sprout-
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d (E) iFig. 4. Grading of neuronal damage in the hippocampal formation of pilocarpine-t
pilocarpine injection. (A) grading of the lesion (n=18) from non-detectable (ND) to
the complete description of themethod). Sections of an intact subiculum (B) and of a
(E) dentate gyrus; note that the section in (E) presents a grade IV lesion in the hilus
with the lateral entorhinal cortex in control (F) and pilocarpine-treated rats (G). Note
(arrow). In (F) and (G), apart the sparse layer IV located immediately above the lam
parasubiculum. Scale bars for panels (B) and (C), (F) and (G) are 250m; for (D) an
subﬁelds; DG: dentate gyrus; DH: dentate hilus; medEC: medial entorhinal cortex; latEC:
ing without cell loss (Gombos et al., 1999). Intriguingly, it has
also been proposed that epileptogenesis may occur without neu-
ronal cell loss (Zhang et al., 2002). In these experiments, kainic
acid-pilocarpine-treated epileptic rats did not exhibit mossy ﬁbre
sprouting.
3. Pilocarpine doses
Behavioural alterations induced by pilocarpine are known to be
dose-dependent. A number of studies have compared doses of pilo-
carpine ranging from 100 to 400mg/kg in adult male Wistar rats
(Turski et al., 1983a; Liu et al., 1994b). Irrespective of the dose, the
animals ﬁrst became immobile, and this was followed by gusta-
tory and olfactory automatisms (salivation, oro-facial movements,
and vibrissae twitching). Subsequently, animals experienced lim-
bic motor seizures, but only with the highest dose of pilocarpine
(400mg/kg) (Turski et al., 1983a; Cavalheiro et al., 1987; Liu et
al., 1994b). Higher doses resulted in a greater likelihood of induc-
tion of the complete syndrome and reduced latency to SE, but alsorats performed in toluidine blue-stained sections that were cut 3 weeks after the
t complete lesion (grade IV) is shown for different areas (see Biagini et al., 2005 for
II-damaged subiculum (C). Non-epileptic control (NEC) (D) and pilocarpine-treated
a well-preserved granule cell layer. Medial entorhinal cortex close to the boundary
) the reduced thickness of layer III, in which neurons are replaced by a glial inﬁltrate
issecans (asterisk), the other cortical layers are indicated at the boundary with the
s 200m. Abbreviations in this ﬁgure: CA1–2, CA3: Cornu Ammonis hippocampal
lateral entorhinal cortex; Sub: subiculum.
increased mortality rate (Clifford et al., 1987; Liu et al., 1994b). In
Sprague–Dawley rats pilocarpine 400mg/kg induced SE in 83% of
animals and mortality was 100% (Jope et al., 1986).
Alterations in EEG recordings have also been reported to be
dose-dependent, occurring in two stages. Low voltage fast activ-
ity ﬁrst appeared in the cortex and amygdala, concurrent with
theta rhythm in the hippocampus. High voltage fast activity then
superseded hippocampal theta, and isolated high voltage spikes
were initially registered exclusively in the hippocampus. In ani-
mals treated with low doses of pilocarpine (100–200mg/kg) this
scenario persisted up to 2h, and the normal EEG proﬁle recovered
immediately after. Animals receiving the highest dose of pilo-
carpine (400mg/kg) exhibited electrographic seizures that were
preceded by high voltage fast activity and prominent high voltage
spiking, followed by variable periods of depression (Fig. 2). These
changes originated in the hippocampus and rapidly spread to the
amygdala andneocortex. Electrographic activity progressively built
up into a SE after 1–2h. This pattern persisted for 5–6h and was
followed by a progressive normalization. Twenty-four hours later,
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animals receiving thehighest dose of pilocarpine exhibited residual
theta rhythm in the hippocampus (Turski et al., 1983a).
Neuropathological consequences were also different in animals
that were treated with different doses of pilocarpine. Damage,
which was conﬁned to piriform cortex and anterior olfactory
nuclei when rats were injected with the lowest dose of pilocarpine
(100mg/kg), extended to amygdala, cortical and basal nuclei, with
200mg/kg, although limbicmotor seizureswere not observed. Rats
that display severe limbic motor seizures after 200mg/kg, showed
additional damage in medio-dorsal thalamic nuclei and in neocor-
tex. Injection of pilocarpine 400mg/kg resulted in the profound
neuropathological alterations already described in the previous
section (see also Turski et al., 1983b).
4. Routes of administration of pilocarpine
It has been demonstrated that intra-hippocampal pilocarpine
administration is as efﬁcient as the i.p. route in inducing SE and
then chronic epilepsy. In fact, animals receiving pilocarpine directly
into the hippocampus show not only the same behavioural, elec-
trographic and neuropathological alterations exhibited by those
treated systemically, but have the advantage of a drastically
reduced mortality (Furtado et al., 2002). Indeed, the ratio of ani-
mals developing SE and surviving after the intra-hippocampal
injection has been found to be higher (71%) than with sys-
temic administration. In Wistar rats injected intra-hippocampally
with pilocarpine (2.4mg/l) in 1l, the ﬁrst epileptiform dis-
charge occurred in the hippocampus and spread to the amygdala,
and was associated with oro-facial automatisms. Epileptiform
discharges observed during SE were characterized by clonic
movements of the head and forelimb that were mirrored by
a larger amplitude signal in amygdala than in hippocampus.
Approximately 70% of the animals experienced SE within 30min
after the intra-hippocampal injection and presented SRSs after a
latent period of 2–30 days. All rats showed positive neo-Timm
staining in the internal molecular layer of the dentate gyrus,
indicating mossy ﬁbre sprouting. In addition, in some of these
animals there was stronger staining in the ventral hippocam-
pus ipsilateral to the site of pilocarpine injection (Furtado et al.,
2002).
Pilocarpine is used also in vitro to induce epileptic activity in
hippocampal neuronal networks. In rat brain entorhinal cortex-
hippocampal slices, pilocarpine at 10M was able to induce an
electrographic activity characterized by different types of epilep-
tiform activity: (i) one type, resembling the interictal activity
observed in epileptic patients when not presenting with seizures,
occurred at 0.2–0.4Hz simultaneously in the entorhinal cortex
and hippocampus; (ii) a second type of interictal discharge only
occurred in the hippocampus at 0.6–3.8Hz; (iii) the third type was
an ictal-like discharge recorded in both entorhinal cortex and the
hippocampus, lasting 4–18 s. Analysis of the time delay demon-
strated the onset of ictal discharges in the entorhinal cortex, from
where they propagated to the dentate area and, ﬁnally, to the hip-
pocampus (Nagao et al., 1996). These results were obtained at a
low extracellular potassium concentration (3.25mM). In contrast,
Marchi et al. (2007) were unable to induce any seizure-like activ-
ity when applying acutely pilocarpine on rat hippocampal slices
in presence of 4.35mM potassium, whereas seizures occurred by
increasing potassium up to 6mM. However, Marchi et al. (2007)
used slices obtained in the coronal plane at dorsal hippocampal lev-
els, instead of the horizontal entorhinal cortex-hippocampal slices
studied in the previously described experiment (Nagao et al., 1996).
Pilocarpine has also been shown to induce bursting activity in CA1
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in which other molecular features of pilocarpine-induced changes
were equally reproduced (Poulsen et al., 2002).
5. Duration of status epilepticus
It has been shown that the duration of SE during the initial
insult is critical to the development of SRSs and brain damage.
However, the different protocols of drug treatment used in differ-
ent studies have resulted in contrasting ﬁndings. The ﬁrst study to
address the effects of SE durationwas conducted in adultmaleWis-
tar rats injected with a single dose of pilocarpine (300–320mg/kg,
i.p.) followed by a combined diazepam (10mg/kg) and pento-
barbital (30mg/kg) treatment (Lemos and Cavalheiro, 1995). This
study reported a progressive increase in the mean latency to the
ﬁrst spontaneous seizure and a decrease in seizure frequency in
animals with shorter SE (1 and 2h). In addition, these animals
presented less severe neuropathological alterations (Lemos and
Cavalheiro, 1995). Finally, this study also showed that there was
a minimum duration of SE prerequisite for the development of
chronic epilepsy; animals experiencing only 30min of SE did not
develop SRSs.
These ﬁndings are at odds with our data (Fig. 3) as well as with
those of Klitgaard et al. (2002), who have observed SRSs in rats
that had experienced 30min SE. The latent period in these animals
lasted 3 weeks and they presented with brain lesions. In animals
that experienced 1h of SE, disruption of the hippocampal pyrami-
dal layer was also observed (Klitgaard et al., 2002). In some cases,
cells were severely shrunken and darkened. Extensive pathologi-
cal alterations were found in the hippocampus, basal amygdaloid
nucleus, dorso-medial thalamic nucleus, substantia nigra, parietal
and temporal neocortex, piriform and entorhinal cortex of animals
that underwent longer SE (up to 6h), indicating that the severity
of neuropathological changes increasedwith increasedSEduration.
Similar observationshavebeen reportedbyothers (Liu et al., 1994b;
Lemos and Cavalheiro, 1995). In Klitgaard et al. (2002) experi-
ments, SE was terminated by injecting diazepam intravenously at
10mg/kg, while other authors generally used the i.p. route and
doses ranging from 5mg/kg (Wozny et al., 2005) up to 20mg/kg
(Gofﬁn et al., 2007), with single or repeated injections. In particu-
lar, Lemos and Cavalheiro (1995) used a combination of diazepam
and pentobarbital, which could bemore efﬁcient in terminating SE
(Morrisett et al., 1987).6. The lithium–pilocarpine model
Variations of the pilocarpine model have been established
by combining this convulsant with other drugs, such as lithium
(3mEq/kg in 0.1–0.2ml of saline, s.c.; Honchar et al., 1983),
picrotoxin (0.5–2.0mg/kg, i.p.; Hamani and Mello, 1997, 2002),
cycloheximide (1mg/kg, s.c.; Longo and Mello, 1997; Longo et
al., 2002), MK-801 (Hughes et al., 1993) and N omega-nitro-l-
argininemethyl ester (1–125mg/kg, i.p.; Starr and Starr, 1993). The
lithium–pilocarpine combination has been the most widely used.
Lithiumisextensivelyusedasmoodstabilizer inmaniac-depressive
illness, and it has beenmore recently introduced in the treatment of
acute brain injuries and chronic neurodegenerative disease (Wada
et al., 2005).
Lithium is generally administered 24h before the SE induc-
tion, and it allows a conspicuous reduction of the pilocarpine
dose required to induce seizures (30mg/kg). The sequence of
behavioural changes observed in animals undergoing a SEwas very
similar for lithium–pilocarpine compared to pilocarpine adminis-
tered alone: it was characterized by staring, head bobbing, blinking
and wet-dog shakes; seizures subsequently appeared 30min later,
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each lasting approximately 30–45 s and recurred every 2–5min
(Honchar et al., 1983; Jope et al., 1986; Clifford et al., 1987). It
has been reported that animals treated with lithium+pilocarpine
showed a decreased variability in time to SE onset (Clifford et al.,
1987).
Staring observed in lithium–pilocarpine-treated animals was
associated with single spikes in the EEG, followed by generalized
spike activity separated by intermittent low voltage activity, after
which spike trains became continuous (Jope et al., 1986). In some
animals, the ventral forebrain (ventral globus pallidumandnucleus
accumbens) was the apparent site of origin for electrographic
seizures that then spread to other areas. In other animals, electro-
graphic seizures began simultaneously at multiple sites (Clifford et
al., 1987). However, there were no differences concerning the pres-
enceof a singleversusmultiple sites of origin in lithium–pilocarpine
and high-dose pilocarpine treatment groups (Clifford et al., 1987).
Neuronaldamage resulting fromSEwasessentially similar in the
lithium–pilocarpine and high-dose pilocarpine models (Clifford et
al., 1987). Thus, the syndromes produced by lithium–pilocarpine
and high-dose pilocarpine treatments are behaviourally, metaboli-
cally, electrographically andneuropathologically indistinguishable.
The major apparent difference seems to be in the increased sensi-
tivity to pilocarpine in lithium-pretreated rats (Clifford et al., 1987).
Also, the rate of success in developing tonic–clonic seizures and SE
after lithium pretreatment is 100%, an improvement when com-
pared with what is seen by employing high-dose of pilocarpine
where it is around 60% (Gofﬁn et al., 2007). Andre´ et al. (2007)
have recently characterized the time course of the neuropatho-
logical changes occurring in magnetic resonance imaging (MRI) of
the brain of lithium–pilocarpine-treated rats. In this study, early
changes in MRI scans were ﬁrst detected in the piriform cor-
tex, entorhinal cortex, thalamus and amygdala 6h after SE. The
hippocampus appeared to be affected only 36–48h later; these
hippocampal alterations appeared, however, to intensify progres-
sively until 80 days after SE. MRI changes also reappeared in the
parahippocampal cortex with SRS onset.
Unfortunately, in the lithium–pilocarpine model the mortality
rate remained very high (92% in Jope et al., 1986; >95% inMorrisett
et al., 1987) when pilocarpine was given in a dose of 30mg/kg
(see Table 1). Decreasing the dose of pilocarpine in lithium-treated
rats resulted in a decrease in mortality rate, but this was con-
comitant with a fall in the success rate for inducing SE (both at
50%; Jope et al., 1986). Neither lithium (3mEq/kg) nor pilocarpine
(30mg/kg) caused abnormal EEG responses when administrated
alone (Jope et al., 1986; Clifford et al., 1987). Additionally, invert-
ing the order of pilocarpine and lithium administration resulted
in no seizures, although co-administration of the agents produced
seizures in three out of ﬁve rats. Finally, lithium pretreatment is
effective onlywhenpilocarpine is administeredwithin 24h; in fact,
the animals did not display seizures when pilocarpine was given
48h after lithium (Clifford et al., 1987).
A further modiﬁcation of the lithium pilocarpine protocol has
also been proposed. Glien et al. (2001) administered lithium fol-
lowed by pilocarpine 24h later. If pilocarpine was administered as
a single dose of 30mg/kg and SE duration was limited to 90min,
mortality was 45%, and 80% of survivors developed SRS. However,
if pilocarpine was given in divided doses of 10mg/kg at 30min
intervals until SE ensued, mortality was reduced to 7%, and 85% of
animals developed SRS. One of us (RSGJ) has been using a further
modiﬁcation of this protocol in which the divided doses of pilo-
carpine have been reduced to 5mg/kg. In addition, when animals
develop SE, they are administered a low dose of the central muscle
relaxant, xylazine,which reduces the severity of clonicmuscle con-
tractions without affecting electrographic seizures (see Yang et al.,
2006; Thompson et al., 2007). Using this approach we have beene Methods 172 (2008) 143–157
able to routinely obtain mortality rates of zero in groups of both
rats andC57BL/6mice (Woodhall, G.L. and Jones, R.S.G. unpublished
results) with a 90–100% success in generating SRSs.
7. Pilocarpine in combination with other drugs
7.1. Pretreatments
7.1.1. Anticholinergic drugs
Administration of the muscarinic antagonist, atropine
(1–5mg/kg, s.c.), to lithium-pretreated rats 30min prior to
pilocarpine prevented the induction of SE along with cell damage
(Clifford et al., 1987; Morrisett et al., 1987). When pretreatment
time is reduced to 15min, seizure activity was induced in 75% of
the animals (Jope et al., 1986). Administration of atropine methyl-
bromide (5mg/kg, i.p., 20min prior to pilocarpine) has been used
to block the peripheral cholinergic side effects of pilocarpine, with-
out interfering with the development of SE and chronic seizures
(Kobayashi et al., 2003; Kumar and Buckmaster, 2006; Kwak et
al., 2006). The antimuscarinic drug, alpha-methylscopolamine
does not cross the blood brain barrier so it cannot interfere with
the central actions of pilocarpine (Clifford et al., 1987). Alpha-
methylscopolamine administered 30min prior the pilocarpine has
therefore been widely used to minimize peripheral cholinergic
activation.Without this pretreatment, animals exhibit classic signs
of peripheral cholinergic stimulation, including piloerection, sali-
vation, tremor, chromodacryorrhea and diarrhea after pilocarpine
injection (Clifford et al., 1987). There is no evidence that low doses
(1mg/kg) of alpha-methylscopolamine alter central effects of
pilocarpine, but higher doses (i.e., 10mg/kg in mice and 20mg/kg
in rats, s.c.) can prevent induction of SE (Turski et al., 1983a,b,
1984).
7.1.2. Antiepileptic drugs
Diazepam (5 or 10mg/kg) prevents the development of
behavioural and EEG alterations induced by pilocarpine as well
as the subsequent neuropathological alterations in both lithium-
pretreated and high-dose pilocarpine rats (Turski et al., 1983a; Jope
et al., 1986; Morrisett et al., 1987) or mice (Turski et al., 1984). An
extended study of the effects induced by different classes of drugs
able to affect seizure onset has been reported by Morrisett et al.
(1987). This study showed that phenobarbital (32.5mg/kg), carba-
mazepine (100mg/kg) and paraldehyde (0.3mg/kg) were able to
prevent SE when administered 15min prior to pilocarpine. Pheny-
toin (200mg/kg) prevented SE in two out of a total of three rats and
prolonged the latency to seizure in the remaining rat. Sodium val-
proate (300mg/kg) increased the latency to seizure initiation but
was ineffective in preventing SE (Morrisett et al., 1987).
7.2. Post-treatments
7.2.1. Anticholinergic drugs
The ability of a number of drugs to halt pilocarpine-induced
SE has been tested. Muscarinic receptor antagonists are generally
ineffective in terminating seizures once SE is established. Atropine,
injected 20min following pilocarpine in lithium–pilocarpine-
treated rats did not alter SE development and all animals
subsequently died (Morrisett et al., 1987). This ﬁnding is in agree-
ment with results obtained in patients suffering SE, in which
anticholinergics were also ineffective (Jope et al., 1986). In con-
trast, administration of atropine, around the time when forelimb
clonus starts, terminated seizures and all animals survived (Jope
et al., 1986; Clifford et al., 1987). Similar results were obtained
with scopolamine (10mg/kg), which failed to prevent or reduce
sciencG. Curia et al. / Journal of Neuro
pilocarpine-induced seizures inmicewhen injected after high dose
pilocarpine (Turski et al., 1984).
7.2.2. Antiepileptic drugs
SE is a life-threatening clinical emergency in human patients
and efﬁcacious treatments are required to treat it. AEDs for treat-
ment of SE have largely been tested in the pilocarpine model.
Morrisett et al. (1987) has shown that diazepam (20mg/kg),
phenobarbital (32.5mg/kg), phenytoin (100mg/kg), valproate
(300mg/kg) and carbamazepine (100mg/kg) are unable to halt
SE in lithium–pilocarpine-treated rats. In contrast, paraldehyde
(0.3mg/kg, intramuscular) is effective. The efﬁcacy of paraldehyde
treatment has been conﬁrmed recently by others (Kubova´ et al.,
2005).
Jones et al. (2002) have suggested that diazepam is inef-
fective when administered 15min after SE is initiated, because
animals develop pharmacoresistance. On the other hand, it has
been found thatdiazepam(10mg/kg), co-administeredwithpento-
barbital (30mg/kg; Lemos and Cavalheiro, 1995) or with phenytoin
(60mg/kg; Fujikawa, 1996) can terminate both motor and elec-
trographic seizures in pilocarpine-treated rats. However, 2h after
diazepam plus pentobarbital treatment, the EEG returned to nor-
mal only in those animals subjected to a SE of 1h or less. SEs of
longer durationwere associatedwith longer recovery periods. Ani-
mals, with SE lasting longer than 1h, later developed SRSs and
morphological alterations typical of the chronic model (Lemos and
Cavalheiro, 1995). Interestingly, Gofﬁn et al. (2007) have reported
that diazepam (20mg/kg) administered after 2h of SE was able to
terminate electrographic seizures in 3–4h.
It appears that diazepam is less effective in terminating motor
seizures compared to other drugs, such as paraldehyde (Morrisett
et al., 1987; Biagini et al., 2001; Kubova´ et al., 2005), or to com-
binations of diazepam with barbiturates (Lemos and Cavalheiro,
1995; Fujikawa, 1996; Biagini et al., 2001). Nevertheless, a single
diazepam injection (20mg/kg, i.p.) 30, 60, 120 or 180min after
the SE onset elicited signiﬁcant differences in mortality and SRSs
depending on SE duration (Figs. 1 and 3). When diazepam was not
applied, SE remitted spontaneously within few hours after pilo-
carpine treatment (Lemos and Cavalheiro, 1995).
8. Phylogenetic characteristics
8.1. Species dependencyRats and, to a lesser extent, mice represent the animal species
used most frequently to reproduce this animal model of TLE. The
acute behavioural andEEG features of pilocarpine-induced seizures
are generally similar in these two species. Following SE induced by
pilocarpine (340mg/kg), adult (25–30g) male albinomice, mortal-
ity rate was 25–50%, mean latent period was 14.4 days, SRSs lasted
50–60 s and they occurred with a frequency of 1–5 seizures per
week (compare Cavalheiro et al., 1991 vs. 1996 and Turski et al.,
1984). It should be emphasized that mice and rats show similar
dose-dependent responses to pilocarpine; in addition, in both cases
only the highest doses of pilocarpine were able to induce recurrent
SRSs at a later stage. However, mice may be more sensitive to pilo-
carpine because the dose needed to provoke seizures is very close
to the lethal dose (Turski et al., 1983a, 1984). In fact, contrary to the
situation in rats, even the lowest dose of pilocarpine (100mg/kg)
wasunable to inducebehavioural alterations in everymouse tested.
Mice receiving 200–300mg/kg of pilocarpine were motionless,
displayed body tremor and occasionally showed myoclonus of
hindlimbs. Following325mg/kg,myoclonic seizures couldbe rarely
observed. However, clonic–tonic seizures leading to death were
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with 350 and 400mg/kg of pilocarpine, respectively. Furthermore,
motor limbic seizures appearedmore rapidly in the animals treated
with the highest pilocarpine dose.
Progressive damage to various brain regions with increasing
doses of pilocarpine have been observed in mice as in rats. Low
doses of pilocarpine elicited minor behavioural and EEG changes
without inducing detectable pathological alterations. Intermediate
doses (200mg/kg) causedmild damage largely conﬁned to the piri-
formcortexandolfactorynuclei,whilstwith thehighestdoses (300,
325 and 350mg/kg) consistent and long-lasting behavioural and
EEG changes (including motor limbic seizures and limbic SE) and
extensive pathological alterations (localized in the olfactory cortex,
thalamus, amygdaloid complex, hippocampal formation, neocortex
and substantia nigra) were observed (Turski et al., 1984).
Pilocarpine has been tested as a convulsant in other species.
In the guinea pig “whole-brain” preparation, seizures have been
evoked by millimolar concentrations of pilocarpine or by break-
down of blood brain barrier (Uva et al., 2008). Similar ﬁndingswere
reported by Marchi et al. (2007), suggesting that pilocarpine in
this model is not epileptogenic per se, but it needs the presence
of cofactors able to increase neuronal excitability. In particu-
lar, Marchi et al. (2007) reported increased blood brain barrier
permeability as well as enhanced production of inﬂammatory
mediators, such as interleukin-1, in rats treated systematically
with pilocarpine. In contrast, pilocarpine was successful in imma-
ture rabbits and results of these experiments will be discussed in
the following chapter on pilocarpine and ontogenesis (see Section
9).
8.2. Strain dependency
Most studies have been carried on Wistar rats. However, results
from Sprague–Dawley rats have not shown major differences in
the development of behavioural and electrographic alterations
(Honchar et al., 1983; Jope et al., 1986), while ameliorating the
mortality rates (Table 1). Pilocarpine effectswere insteadmore pro-
nounced in Long-Evans rats, inwhich a highermortality rate, larger
damage to thehippocampusandabehavioural outcomeworse than
in Wistar rats was found (Hort et al., 2000).
Shibley and Smith (2002) have conducted a detailed study com-
paring the pilocarpine model in two different mouse strains. They
showed that SE in C57BL/6 inbred mice was delayed compared to
CD-1 outbred mice. However, the mean number of seizures, the
time toonset of SRSs and the frequencyof SRSswere similar.Miceof
either strain that experienced less than3 seizures after the injection
did not develop chronic epilepsy. In addition, the frequency of SRSs
was related to the seizure frequency exhibited 2h after the pilo-
carpine treatment for both CD-1 and C57BL/6 mice. Robust mossy
ﬁbre sprouting in the innermolecular layerwas observed in all ani-
mals that developed spontaneous seizures. Cresyl violet staining of
brain tissue from CD-1 and C57BL/6 mice suggested that the distri-
bution of cell loss in the temporal hippocampus was similar to that
observed in rats and in albino mice (Shibley and Smith, 2002).
A different proﬁle of responses to pilocarpine injection was
found in mice belonging to different inbred strains (Table 2).
According toWinawer et al. (2007),mice belonging to the A/J strain
more frequently developed SE, although with a longer latency,
when compared to DBA mice. Differences were also found in the
survival rate of these different strains: DBA survived to SE but pre-
sented higher mortality in the chronic period, while A/J mice were
less able to cope with SE and the mortality rate was found to be
dose-dependent by varying pilocarpine from 200 to 300mg/kg.
Neuronal cell loss was more pronounced in the CA1 and CA3
pyramidal cell layer of DBA mice, which presented also enhanced
proliferation of ectopic granule cells. In another work (Chen et al.,
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Table 2
Differences in the response to pilocarpine in various mouse strains
Strain Tonic-clonic seizure stage 5 (%) Mortality (%) Neuro
C57BL/6 100 21 ++
42.9 19 ++
CD1 61.5 21 ++
23.5 29.4 ++
FVB/N 55.6 60.3 +
A/J 100 75 +++
DBA 90 17 +++
In agreement with ﬁndings in rats, the mouse strain greatly affects the response in
probability to get fully developed seizures is also greatly affected by the mouse strai
mice than in rats with the exception of A/J and DBA inbred strains. Note that CD1 is
2005), the inbredmouse strain FVB/Nwas compared with C57BL/6
and CD-1, demonstrating a better response in terms of successful
development of SE (FVB/N vs. CD-1) but a worse outcome for mor-
tality (FVB/N vs. C57BL/6). In general, FVB/N mice presented larger
hippocampal damage and, curiously, a stronger reactive gliosis.
9. Ontogenetic characteristics
Evidence obtained from different studies shows that
behavioural and EEG changes following systemic administra-
tion of pilocarpine to rats (Cavalheiro et al., 1987; Priel et al.,
1996) are age-dependent. There is, however, controversy over the
minimum age needed to develop the full syndrome for a chronic
model of epilepsy. In addition, there are concerns on the validity of
modeling seizures in the ﬁrst 2weeks postpartum, as in this period
the hypothalamo–pituitary–adrenal axis is immature in rodents
(Sapolsky and Meaney, 1986; Vazquez, 1998) but not in humans
(Gunnar and Donzella, 2002). Thus, plasma corticosterone levels,
which are still elevated at P1, decrease to a minimum at P3 and are
not increased by stress stimuli until P12 (Sapolsky and Meaney,
1986). Glucocorticoids are known to enhance the lesion caused by
several agents in the hippocampus (Sapolsky, 2000). Metyrapone,
an inhibitor of glucocorticoid production, was shown to reduce
loss of pyramidal cells in CA1 after kainic acid induction of SE
(Smith-Swintosky et al., 1996). In agreement with these ﬁndings,
P10 rat pups presenting with higher corticosterone levels devel-
oped more cognitive defects after SE induced by administration of
lithium–pilocarpine (Lai et al., 2006).
A number of studies have investigated seizure effects from
the ﬁrst week postpartum until puberty. Cavalheiro et al. (1987)
demonstrated that pilocarpine (100–380mg/kg)-induced hypoac-
tivity, head and whole body tremors, loss of righting reﬂex and
scratching movements for up to 90min in 3–6-day-old Wistar rats.
There was no evident relationship between dose and behavioural
changes. The same doses induced in 7–12-day-old rats more com-
plex changes that lasted for 1–2h. In animals at P11-12, pilocarpine
(200mg/kg) induced forelimbclonus, headbobbing and loss of pos-
tural control and motor seizures in 11 out of 16 rats, 4 of which
evolved into SE. At P24–60, rats presented with the same proﬁle as
adult animals (cf. Turski et al., 1983a; Liu et al., 1994a). However,
the latent period was shorter in older animals (Priel et al., 1996).
Mortality also appears to be age-dependent. InWistar rats itwas
high between P15 and 21 (when the success rate in inducing SE is
higher) and lower in younger (whenno SE is inducible) or older ani-
mals (Cavalheiro et al., 1987). Priel et al. (1996) have also reported a
highermortality rate in rats at P18 and 35,when young animals had
a better probability of developing SRSs. Rat pups (P7–17) presented
lower mortality rates but did not develop SE and SRSs; peripuber-
tal and pubertal rats gradually approximated the mortality rate
observed in adults and more frequently became epileptic (Priel ete Methods 172 (2008) 143–157
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s of mortality rate, that was found to be higher in FVB/N and A/J inbred mice. The
in this case, variability is very large. Neuronal loss is, in general, less pronounced in
nly outbred strain characterized in these studies. + mild; ++ moderate; +++ severe.
al., 1996). According to another report, increase in seizure suscepti-
bility occurred primarily after P100 (Patel et al., 1988). In contrast,
Ferreira et al. (2003) observed permanent absence-like epilepsy
in adult rats that experienced pilocarpine-induced SE between
P7 and 17 days; they found no difference in the behavioural
responses, EEG and the spontaneous seizures observed in groups
of different age. Spike-and-wave discharges occurred bilaterally in
the neocortex, concomitantly or not with staring, and occasionally
with clonic movements or single jerks (Ferreira et al., 2003).
Electrographic changes display more complex patterns in older
versus younger rats. Pilocarpine (380mg/kg) induced ﬂattening of
background activity at P3–6 and electrographic seizures at P11–12.
Rats at P15–21 displayed seizure activity starting in the hippocam-
pus and rapidly spreading to the neocortex after a short delay.
SE was reached more rapidly in 15–21-day-old rats than in older
animals. Nomorphological alterations have been reported in 3–10-
day-old rats treated with pilocarpine up to 380mg/kg. Only 5 of
14, 11–21-day-old rats that went through SE presented with some
brain damage and the extent of this was less than that in adult rats.
P24–60 rats presented with damage that was more similar to that
observed in adult animals (Cavalheiro et al., 1987). In this study
behavioural and EEG changes have been investigated only during
the acute period. These data have been conﬁrmed by Priel et al.
(1996), who found that 7–17-day-old Wistar rats do not develop
SRSs even when all of them received a high dose of pilocarpine
(380mg/kg). The latency to the appearance of the ﬁrst seizure was
longer in younger animals when compared to adult rats. The per-
centage of animals experiencing SRSs was higher when animals
were injected at P50–120, and it decreased in younger rats. In addi-
tion, SRS frequency in the chronic phase was lower in the younger
animal group (Priel et al., 1996). Hence, an age-dependent pro-
gression of seizure-related brain damage has been observed, with
damage more severe in mature animals than in younger rats (Priel
et al., 1996).
Epileptic activity, hippocampal damage and supragranular
sprouting were not seen in P7–11 rats after a single dose of
pilocarpine. However, three consecutive pilocarpine-induced SE
episodes, during P7–9, induced an epileptic condition later in
the life (Dos Santos et al., 2000; da Silva et al., 2005a). Single
injections of pilocarpine for three consecutive days in P7–9 Wistar
rats induced body tremor, scratching, forelimbs clonus and head
bobbing that culminated in SE in all animals. Some experienced
tonic–clonic convulsions that appeared to be more frequent after
the second and third injection. Mortality with this approach was
0%. These animals displayed EEG alterations accompanied by
motor seizures. Apoptotic neurons, corresponding to hippocampal
interneurons, were identiﬁed in the dentate hilus (Dos Santos et al.,
2000). EEG recordings made 1month or more after the pilocarpine
injections, have revealed abnormalities devoid of behavioural
correlates. This activity was more intense and long-lasting in
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animals that presentedwith tonic convulsions during SE. However,
the severity of the electrographic epileptiform features increased
with age, being longer andmore pronounced in older animals (Dos
Santos et al., 2000). Interestingly, in the study by Dos Santos et
al. (2000) animals exhibited hippocampal damage and developed
complex partial seizures, but rats receiving the same treatment
in another study (da Silva et al., 2005b) were found to undergo
generalized electrographic seizures without marked hippocampal
damage.
It seems likely that the occurrence of SE episodes during
development induced complex cellular changes that can alter
the maturation of neocortical and hippocampal circuits. In fact,
developing rats, submitted to three consecutive episodes of
pilocarpine-induced SE on P7, 8 and 9, presented with several
long-lasting changes in neocortical architecture that could under-
lie the behavioural characteristics and the generalized epileptic
discharges observed later in adulthood (da Silva et al., 2005b).
The most prominent changes were altered intracortical micro-
circuitry development, decreased parvalbumin-positive cells in
CA1 and dentate gyrus, increased glutamic acid decarboxylase 65
immunoreactivity in neocortex and altered neocortical apoptotic
processes (da Silva et al., 2005b).
Administration of pilocarpine (30mg/kg) to lithium-treated rats
aged at P11–30, induced SE in all animals. Mortality was zero for
animals between P11 and 14, and this increased to 33% and 50% in
animals at P15–21 and P22–30, respectively. Higher doses of pilo-
carpine (60mg/kg) evoked SE in all the animals, but with higher
rates of mortality (67% at P11–14, reaching 100% at P15–21; Hirsch
et al., 1992). Rats that experienced lithium–pilocarpine-induced SE
at P10 did not develop SRSs and did not show any neuronal dam-
age, but all adult rats undergoing lithium–pilocarpine-induced SE
developed SRSs after a mean latent period of 24.9 days.
Signiﬁcant neuronal loss was observed in hippocampus, baso-
lateral and medial nuclei of amygdala, piriform cortex and lateral
thalamic nucleus. Among rats exhibiting lithium-pilocarpine
induced SE at P21, three groups of rats could be distinguished 2–3
months later (Dube´ et al., 2001). The ﬁrst group developed SRSs
after a mean period of 74 days and the behavioural manifestations
were very similar to those seen in adult rats. Rats in the second
group did not develop SRSs but seizures could be triggered by
stress. The third group developed neither SRSs nor stress-induced
seizures. Signiﬁcant neuronal damage was observed in the hilus of
all three groups. Cell loss was found in the medial amygdala and
layer II of the entorhinal cortex in the group without any seizures,
and in the lateral thalamus and layer III–IV of the entorhinal cortex
in rats that showed SRSs. Damage in layer II of the entorhinal cortex
was seen in the triggered seizure group (Dube´ et al., 2001). In the
same study all adult rats injectedwith lithium–pilocarpine became
epileptic and suffered massive and widespread cellular damage
(Dube´ et al., 2001).
In two reports originating from different laboratories
(Thompson and Wasterlain, 1997; Towﬁghi et al., 2004),
lithium–pilocarpine was tested in immature rabbits to assess
any possible advantage compared to immature rats in seizure
induction and sensitivity to neuronal damage. In the ﬁrst study,
P9 New Zealand White rabbit pups were treated with lithium
(3mEq/l, s.c.) and the following day with atropine methylbromide
(1mg/kg, s.c.) followed 15min later by pilocarpine (200mg/kg,
i.p.). Approximately 80% of the animals suffered recurrent episodes
of clonic seizures and postural alterations consisting of splaying
of the limbs. The remaining animals exhibited a more severe
response, with loss of posture and tonic–clonic seizures. In both
cases, however, SE was not attained. Mortality was around 40%,
and 65% of surviving rabbits presented neuronal loss in CA1 and,
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damage was also noted (Thompson and Wasterlain, 1997), thus
these authors concluded that the immature rabbit was a better
model to investigate seizure-induced damage than the neonatal
rat.
In the other report, Towﬁghi et al. (2004) investigated the effects
of pilocarpine treatment during the ﬁrst and the second weeks
postpartum, in the New Zealand white rabbits. The motivation
to investigate rabbits originated from the fact this species, like
humans, appears to be a “perinatal brain developer”. Groups of
rabbits at P6–7 or P10–12, received 200–300mg/kg of pilocarpine
after pretreatment with lithium and atropine. Pilocarpine-induced
seizures were scored according to a scale that identiﬁed motor
behaviours such as chewing, tremors and extension of forelimbs
as mild seizures. Recurrent clonic convulsions with splayed legs as
well as robust tonic–clonic convulsions with apnea were scored as
severe seizures. These phenomena persisted for less than 2h and
were accompanied by a moderate mortality (approximately 35%).
In animals exhibiting severe seizures, brain damage was found in
approximately 30% of animals lithium–pilocarpine-treated in post-
natalweek1and inaround65%of theanimals treated inweek2. The
most pronounced lesionswere seen in CA1, followed by the subicu-
lum, neocortex, CA3, basolateral and lateral amygdala and striatum
(only in one animal). Towﬁghi et al. (2004) have also tested kainic
acid as a convulsant, but were unable to induce seizures with this
glutamatergic receptor agonist. Thus these studies again, showed
an age-dependency of the damaging effects of pilocarpine-induced
seizures.
10. Gender
Most laboratories have used male rats to limit the inﬂuences
of variations in the activity of sex hormone-related axes and
also because of the different modulatory effects of testosterone
and estradiol on seizures (Galanopoulou et al., 2003). Studies
aimed at comparing the different responses in Wistar males and
females (Cavalheiro et al., 1987; Mello and Covolan, 1996; Ferreira
et al., 2003) have failed to ﬁnd evidence for any differences in
behaviour, EEG or occurrence of SRSs. However, in another study
Sprague–Dawley female rats were found to be less responsive to
pilocarpine and to present lower mortality rates than male rats
(Mejı`as-Aponte et al., 2002). It is worth to note that the main aim
of the study made by Mejı`as-Aponte et al. (2002) was to compare
susceptibility to seizures in males compared to female. In con-
trast, the other studies (Cavalheiro et al., 1987; Mello and Covolan,
1996; Ferreira et al., 2003) were not aimed at characterizing sex-
dependent differences in the response to pilocarpine, thus the data
obtained from females and males were pooled together. In addi-
tion, major sources of variability in these experiments were the
lack of a precise timing of pilocarpine administration in relation to
the pubertal development or, in mature female animals, in relation
to the ovarian cycle. Fluctuations in female steroids are known to
greatly affect the response to pilocarpine in terms both of survival
and latencies to seizure onset (Valente et al., 2002).
Findings obtained from experiments performed on female rats
in relationship to physiological changes in the sex hormonal
axes, indicate that seizure frequency decreases during pregnancy
and lactation. Signiﬁcant changes in gonadal, hypophyseal and
hypothalamic hormones, as well as reduction in fertility, increase
in mating time and decrease of the gestational period occurred
in female Wistar pilocarpine-treated rats (Amado and Cavalheiro,
1998). In addition, it has been reported that castration interfered
with epileptogenesis in the pilocarpine model of epilepsy (Valente
et al., 2002). In fact these authors observed an increased mortal-
ity rate during SE, shorter latent period, and more pronounced
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hippocampal cell loss in castrated animals. These data suggest
that female sexual hormones may have protective effects against
pilocarpine-induced SE. In line with this view, it has been reported
that ovariectomized females present with increase mortality rate,
shorter time to onset of SE and more pronounced mossy ﬁbre
sprouting (Valente et al., 2002).
11. Discussion
11.1. Homology with TLE aetiology
TLE is a major neurological disease which presents a poor
response to AEDs. In a recent study (Mathern et al., 2002), 54%
of TLE patients undergoing surgical treatment for pharmacoresis-
tance were found to present hippocampal sclerosis only, and 17%
presented hippocampal sclerosis associatedwith another lesion. In
this investigation, 71% of patients with hippocampal sclerosis suf-
feredof seizures in the childhoodor, less frequently, later. According
to Bruton (1988), hippocampal sclerosis is associated with child-
hood febrile convulsions in 55% of TLE patients, birth injury or
cerebral trauma in 24%, and with SE in 18%. In few cases it was
not possible to ﬁnd any “initial precipitating injury” that could be
interpreted as a possible cause of hippocampal sclerosis (Mathern
et al., 2002).
Among the several types of initial precipitating injuries, those
mimicking SE are more feasibly applied in animals in view of the
very simple approach offered by the i.p. injection of a convulsive
drug such as pilocarpine. Thus, these models do not require any
apparatus or particular technical ability, as instead in the case of
cerebral trauma or febrile seizures. For the same reason, they do
not have additional costs apart from drugs and animals. These
characteristics have made the pilocarpine and kainic acid models
particularly appealing. Are these reasons sufﬁcient for considering
thesemodels better than others in mimicking TLE?We believe this
is the case. However, we have also to consider whether SE or pro-
longed seizures are a frequent clinical condition that could thus be
proﬁciently modeled to study TLE.
When considering the original deﬁnition of initial precipitat-
ing injury, indicating any event causing loss of consciousness for
more than 30min or the alteration of cognition formore than 4h, it
turnedout thatmore than40%of injurieswere causedbyprolonged
seizures or SE (Mathern et al., 1997a). Indeed, we have shown that
just 30-min SE (the minimal time interval generally accepted to
deﬁne SE) are enough to reproduce the pilocarpine model (Biagini
et al., 2008). Thus, by reducing the period of seizure duration may
result in a better adherence of the pilocarpine model to the clinical
history of TLE patients.
Another critical point is the age dependency of TLE. Initial pre-
cipitating injuries occur more frequently in the ﬁrst year of age
or, anyway, in the childhood (Mathern et al., 2002). Convulsive
SEs, which occurs in 51/100,000/year children under 1 year of
age, are less frequent in children between 1 and 4 years of age
(29/100,000/year) and drops abruptly over 5 years of age (Raspall-
Chaure et al., 2007). As we described in Section 9, it is difﬁcult to
reproduce all the features of the pilocarpine model until 21 days
of age. Undoubtedly, this is a drawback of the model that depends
on the various differences in central nervous system development
between rodents and humans. Focusing on 3-week-old rats could
provide an improvement in the pilocarpine model homology, but
certainly it will not satisfy the requirement for an ideal model. In
fact, working on young animals could be more expensive and time
consuming than with adult animals, as the young animals present
higher mortality rates and a longer latent period. However, there is
no doubt that the longer latency to SRSs in young animals offers a
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11.2. Homology with TLE pathophysiology
Manypathophysiologicalmechanismsassociatedwithepilepto-
genesis in the pilocarpine model have been demonstrated to occur
also in the human hippocampal formation, including mossy ﬁbre
sprouting, interneuron loss and granule cell dispersion in the den-
tate gyrus (Mathern et al., 1997a;Wieser, 2004). These aspects have
been already considered in previous review articles (Covolan and
Mello, 2000; Avoli et al., 2002; Pitka¨nen and Sutula, 2002). How-
ever, the discussion has generally been focused on the changes
occurring in the hippocampal formation, whereas extrahippocam-
pal lesions have been systematically underevaluated.
In the pilocarpine model, damage is widespread and involves
several brain regions (as illustrated in Sections 2, 3 and 5). The
presence of multiple lesion sites has been considered as a draw-
back of the model (Sloviter, 2005), maybe because the attention
has been focused mainly on hippocampal sclerosis, the hallmark
of TLE. However, neuronal lesions have been described also in the
amygdala, thalamus and neocortex of TLE patients (Mathern et al.,
1997a). Whatever lesion is found, the main question that remains
is inwhichway SRSs are generated in TLE and in the respective ani-
malmodel. To this regard, Zhang et al. (2002) have shown thatwith
repeated subthreshold kainic acid-pilocarpine doses, rats ﬁnally
develop SE and become epileptic without evident neuronal loss
in the major cerebral areas in which damage usually occurs. Thus,
epileptogenesis apparently can take place without any gross lesion
to speciﬁc brain regions.
These data also indicate that the problem is not to set the ideal
model of TLE pathophysiology but to correctly interpreter what
the animal model used is suggesting us that could be relevant for
understanding the mechanisms involved in this disease. Thus, the
various variants of the pilocarpine model could be interesting to
analyse different aspects of TLE. For instance, the model based on
repeated subthreshold kainic acid-pilocarpine injections proposed
by Zhang et al. (2002) is certainly interesting to study the cellu-
lar andmolecular mechanisms involved in epileptogenesis, but not
those that are implicated in neurodegeneration. In contrast, the
standard pilocarpine paradigm is suited to address how damage
develops in selected brain regions during seizures. To this regard, it
has to benoticed that TLEmaybe considered adegenerative disease
as shownby studies that have proven a progression in hippocampal
and extrahippocampal atrophy in relation to the duration of refrac-
tory seizures (Fuerst et al., 2003; Bernasconi et al., 2005; Bonilha et
al., 2006). Interestingly, it has been recently shown the presence of
multiple foci of blood brain barrier damage in the brain of animals
presenting SRSs and in TLE patients refractory to AEDs (van Vliet et
al., 2007).
11.3. Homology with TLE drug treatment
It is well known that hippocampal sclerosis is associated with
a poor response to AEDs in as much as 75% of patients (Spencer,
2002). Thus, an absolute requirement for the pilocarpine model
is the homology with pharmacoresistance. Only a few studies on
pharmacoresistance have been however conducted in pilocarpine-
treated rats. Probably, the reason for such scarce investigation on
this issue is that pilocarpine-treated epileptic rats are rather difﬁ-
cult to be managed because they are very aggressive; in addition,
pilocarpine-treated epileptic rats are also very sensitive to stress
and require a way of drug administration that might prevent the
possibility to elicit seizures.
In the few studies published to date, AEDswere administered by
i.p. injection (Leite and Cavalheiro, 1995; Chakir et al., 2006) or s.c.
via osmotic minipumps (Glien et al., 2002). Leite and Cavalheiro
(1995) were the ﬁrst to administer AEDs to pilocarpine-treated
sciencG. Curia et al. / Journal of Neuro
animals and basically invalidated the usefulness of this model
in mimicking TLE pharmacoresistant patients. As already men-
tioned, other two independent studies observed a poor response
of lithium–pilocarpine-treated female rats to levetiracetam (Glien
et al., 2002) and of pilocarpine-treatedmale rats to carbamazepine
(Chakir et al., 2006), suggesting that the model could be able to
mimic also pharmacoresistance. There is no simple explanation for
these discrepancies, but we have obtained preliminary results that
suggest that the response of pilocarpine-treated epileptic rats to
AED treatment is greatly inﬂuenced by the degree of hippocam-
pal damage (Longo, 2005). This hypothesis is reinforced by data
obtained in a different model of pharmacoresistance in which rats
non responding to phenobarbital presented with neuronal cell
damage in the hippocampus, while those responding to this bar-
biturate had a structurally preserved hippocampus (Volk et al.,
2006).
12. Conclusions
Based on the evidence collected from different laboratories,
it appears that the pilocarpine model may represent a suitable
tool for investigating the pathophysiogenetic mechanisms of TLE.
The initial insult – which may be analogous to febrile seizures,
perinatal hypoxia, infections or head trauma in humans and it is
represented by SE in the pilocarpine model – is followed by the
development of chronic seizures after a latent period of variable
duration. It has been demonstrated that pilocarpine-induced SE,
when not prematurely interrupted by drug administration, is able
to induce anatomical damage and reorganization similar to that
observed in humans affected by TLE. However, since it has been
shown that age, strain, gender, as well as combination with other
drugs canbecritical factors for thedevelopmentof chronic epilepsy,
all these variables have to be carefully controlled to obtain a reli-
able animal model of TLE, as well as for reducing mortality and
variability as far as possible while recreating the full epileptic dis-
order.
It has been underscored that the inconsistencies found in the
way to implement the pilocarpine model in various laboratories
could lead to conclusions that are irrelevant or even misleading
for TLE. In addition, there is danger of ignoring ﬁndings that could
be of help in understanding some aspects of TLE pathophysiol-
ogy. Indeed, the ﬁrst requirement for the pilocarpine model is
face validity with TLE, so the presence of an initial precipitat-
ing injury, a latent period, seizures origin in the temporal lobe
and associated structures and, possibly but not necessarily, the
presence of hippocampal lesions with a topography similar to
what found in the human. The presence of lesions extending in
areas not directly connected with the hippocampus somehow lim-
its the value of this model, especially when substantia nigra is
involved.
We propose that different laboratories should provide a com-
moneffort to limit SEduration (30–60min appears to be enough) to
conﬁneneuronaldamage to thehippocampal formationandrelated
limbic regions. As alreadymentioned, the hippocampus proper, the
entorhinal cortex and the amygdala appear to be the most dam-
aged areas in patients affected by TLE. In this regard, it may also be
important to unify the drug treatment that is employed to termi-
nate SE. As diazepam appears to be the most widely (although not
themost effective) drugused, it should be administered at the same
dose in the various laboratories, possibly at 20mg/kg injected i.p.
in a single administration. Indeed, we have recently obtained evi-
dence that limiting SE to 30minbyquelling seizureswithdiazepam
20mg/kg results in epileptic rats with lesions well conﬁned in the
limbic system (Biagini et al., 2008). We also recommend employ-
ing adult 7–8-week-old Sprague–Dawley rats since these animalse Methods 172 (2008) 143–157 155
are characterized by a higher survival rate when using a 30-min
SE.
Finally, another point is the predictive validity of this model,
i.e. the ability to reproduce the same pattern of responsiveness to
AEDs seen in TLE patients. This point has already been reviewed
extensively (Turski et al., 1989; Loscher, 2002). As discussed
in Section 11, the ability to reproduce pharmacoresistance (i.e.,
to what extent pilocarpine-treated rats develop seizures refrac-
tory to AEDs) remains controversial. According to Glien et al.
(2002), levetiracetam can decrease but not abolish seizures in the
lithium–pilocarpine model. Interestingly, in this experiment lev-
etiracetam was administered via miniosmotic pumps thus ruling
out the possible interference of stress in inducing seizures. This
is an innovative approach to drug administration in epileptic rats
that should be preferred to that based on the i.p. injection of mul-
tiple antiepileptic doses (up to 3/day, Leite and Cavalheiro, 1995;
Chakir et al., 2006), obviously causing more distress (Doheny et al.,
2002). Thus, it could be possible to demonstrate the homology of
thismodelwith the humandisease by showing that different popu-
lations of rats are responsive or not, respectively, to AED treatment.
In this eventuality, the pilocarpine model could serve as a power-
ful tool to predict the response of TLE patients to new antiepileptic
treatments. However, further studies are required to deﬁnitively
clarify this point since different populations of drug-responsive
or drug-resistant rats still have not been found in the pilocarpine
model.
In conclusion, the pilocarpine model of TLE remains an animal
model relevant for the human disease after 25 years from its initial
characterization. Although it has been used by several laborato-
ries in order to investigate the consequences of initial seizures as
well as the processes leading to establish the chronic disease, it has
still to be thoroughly investigated in some aspects intrinsic to the
model, including the relations among several parameters such as
SE intensity, neuronal damage, latent period length and sensitivity
to AEDs. We predict that the contribution of investigators to clarify
these aspects in the pilocarpine model will allow a more rational
approach to understanding the multifaceted aspects of TLE.
Acknowledgments
This study was supported by the Canadian Institutes of
Health Research (CIHR Grant MOP-8109), the Natural Sciences
and Engineering Research Council of Canada (NSERC)/CIHR (Grant
CHRPJ323272-06), the Italian Ministry of Education, University
and Research (Research Project of Relevant National Interest-
PRIN2003), the Savoy Foundation, the Foundation Pierfranco e
LuisaMariani (Milan, Italy) and the Emilia-Romagna Region (PRIER
2007/09). GC was supported by a postdoctoral fellowship from the
Fragile X Research Foundation of Canada in partnership with the
Canadian Institutes of Health Research.
References
Amado D, Cavalheiro EA. Hormonal and gestational parameters in female rats
submitted to the pilocarpine model of epilepsy. Epilepsy Res 1998;32:266–
74.
Andre´ V, Dube´ C, Franc¸ois J, Leroy C, Rigoulot MA, Roch C, et al. Pathogene-
sis and pharmacology of epilepsy in the lithium–pilocarpine model. Epilepsia
2007;48(Suppl 5):41–7.
Arida RM, Scorza FA, Peres CA, Cavalheiro EA. The course of untreated seizures in
the pilocarpine model of epilepsy. Epilepsy Res 1999;34:99–107.
Avoli M, D’Antuono M, Louvel J, Kohling R, Biagini G, Pumain R, et al. Network and
pharmacological mechanisms leading to epileptiform synchronization in the
limbic system in vitro. Prog Neurobiol 2002;68:167–207.
Bartolomei F, KhalilM,Wendling F, Sontheimer A, Regis J, Ranjeva JP, et al. Entorhinal
cortex involvement in human mesial temporal lobe epilepsy: an electrophysio-
logic and volumetric study. Epilepsia 2005;46:677–87.
scienc156 G. Curia et al. / Journal of Neuro
Bernasconi N, Natsume J, Bernasconi A. Progression in temporal lobe epilepsy:
differential atrophy in mesial temporal structures. Neurology 2005;65:
223–8.
Biagini G, Avoli M, Marcinkiewicz J, Marcinkiewicz M. Brain-derived neurotrophic
factor superinduction parallels anti-epileptic—neuroprotective treatment in the
pilocarpine epilepsy model. J Neurochem 2001;76:1814–22.
Biagini G, Baldelli E, Longo D, Baccarani Contri M, Guerrini U, Sironi L, et al.
Proepileptic inﬂuence of a focal vascular lesion affecting entorhinal cortex-CA3
connections after status epilepticus. J Neuropathol Exp Neurol 2008;67:687–701.
Biagini G, Baldelli E, Longo D, Pradelli L, Zini I, Rogawski MA, et al. Endogenous
neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy.
Exp Neurol 2006;201:519–24.
Biagini G, D’Arcangelo G, Baldelli E, D’Antuono M, Tancredi V, Avoli M. Impaired
activation of CA3 pyramidal neurons in the epileptic hippocampus. Neuromol
Med 2005;7:325–42.
Bonilha L, Rorden C, Appenzeller S, Coan AC, Cendes F, Li LM. Gray matter
atrophy associated with duration of temporal lobe epilepsy. Neuroimage
2006;32:1070–9.
Bruton CJ. The neuropathology of temporal lobe epilepsy. New York: Oxford Univer-
sity Press; 1988. p. 176.
Cavalheiro EA, Leite JP, Bortolotto ZA, TurskiWA, Ikonomidou C, Turski L. Long-term
effects of pilocarpine in rats: structural damage of the brain triggers kindling
and spontaneous recurrent seizures. Epilepsia 1991;32:778–82.
CavalheiroEA, SantosNF, PrielMR. Thepilocarpinemodel of epilepsy inmice. Epilep-
sia 1996;37:1015–9.
Cavalheiro EA, Silva DF, Turski WA, Calderazzo-Filho LS, Bortolotto ZA, Turski L.
The susceptibility of rats to pilocarpine-induced seizures is age-dependent. Dev
Brain Res 1987;37:43–58.
Chakir A, Fabene PF, Ouazzani R, Bentivoglio M. Drug resistance and hippocampal
damage after delayed treatment of pilocarpine-induced epilepsy in the rat. Brain
Res Bull 2006;71:127–38.
Chen J, Larionov S, Pitsch J, Hoerold N, Ullmann C, Elger CE, et al. Expression
analysis of metabotropic glutamate receptors I and III in mouse strains with
different susceptibility to experimental temporal lobe epilepsy. Neurosci Lett
2005;375:192–7.
Clifford DB, Olney JW, Maniotis A, Collins RC, Zorumski CF. The functional anatomy
and pathology of lithium-pilocarpine and high-dose pilocarpine seizures. Neu-
roscience 1987;23:953–68.
Covolan L, Mello LE. Temporal proﬁle of neuronal injury following pilo-
carpine or kainic acid-induced status epilepticus. Epilepsy Res 2000;39:133–
52.
da Silva AV, Regondi MC, Cavalheiro EA, Spreaﬁco R. Disruption of cortical develop-
ment as a consequence of repetitive pilocarpine-induced status epilepticus in
rats. Epilepsia 2005a;46(Suppl 5):22–30.
da Silva AV, Regondi MC, Cipelletti B, Frassoni C, Cavalheiro EA, Spreaﬁco R. Neo-
cortical and hippocampal changes after multiple pilocarpine-induced status
epilepticus in rats. Epilepsia 2005b;46:636–42.
Dalby NO, Mody I. The process of epileptogenesis: a pathophysiological approach.
Curr Opin Neurol 2001;14:187–92.
de Guzman P, Inaba Y, Biagini G, Baldelli E, Mollinari C, Merlo D, et al. Subiculum
network excitability is increased in a rodent model of temporal lobe epilepsy.
Hippocampus 2006;16:843–60.
Doheny HC, Whittington MA, Jefferys JG, Patsalos PN. A comparison of the efﬁcacy
of carbamazepine and the novel anti-epileptic drug levetiracetam in the tetanus
toxin model of focal complex partial epilepsy. Br J Pharmacol 2002;135:1425–
34.
Dos Santos NF, Arida RM, Trindade Filho EM, Priel MR, Cavalheiro EA. Epilepto-
genesis in immature rats following recurrent status epilepticus. Brain Res Rev
2000;32:269–76.
Du F, Eid T, Lothman EW, Ko¨hler C, Schwarcz R. Preferential neuronal loss in layer
III of the medial entorhinal cortex in rat models of temporal lobe epilepsy. J
Neurosci 1995;15:6301–13.
Dube´ C, Boyet S, Marescaux C, Nehlig A. Relationship between neuronal loss
and interictal glucose metabolism during the chronic phase of the lithium-
pilocarpine model of epilepsy in the immature and adult rat. Exp Neurol
2001;167:227–41.
EsclapezM, Hirsch JC, Ben-Ari Y, Bernard C. Newly formed excitatory pathways pro-
vide a substrate for hyperexcitability in experimental temporal lobe epilepsy. J
Comp Neurol 1999;408:449–60.
Ferreira BLC, Valle AC, Cavalheiro EA, Timo-Iaria C. Absence-like seizures in adult
rats following pilocarpine-induced status epilepticus early in life. Braz J Med
Biol Res 2003;36:1685–94.
Fisahn A, Pike FG, Buhl EH, Paulsen O. Cholinergic induction of network oscillations
at 40Hz in the hippocampus in vitro. Nature 1998;394:186–9.
Fuerst D, Shah J, Shah A, Watson C. Hippocampal sclerosis is a progressive disorder:
a longitudinal volumetric MRI study. Ann Neurol 2003;53:413–6.
FujikawaDG. The temporal evolution of neuronal damage frompilocarpine-induced
status epilepticus. Brain Res 1996;725:11–22.
FujikawaDG, Shinmei SS, Cai B. Lithium-pilocarpine-induced status epilepticus pro-
duces necrotic neurons with internucleosomal DNA fragmentation in adult rats.
Eur J Neurosci 1999;11:1605–14.
Furtado MdeA, Braga GK, Oliviera JAC, Del Vecchio F, Garcia-Cairasco N. Behav-
ioral, morphologic, and electroencephalographic evaluation of seizures induced
by intrahippocampal microinjection of pilocarpine. Epilepsia 2002;43(Suppl
5):37–9.e Methods 172 (2008) 143–157
Galanopoulou AS, Alm EM, Veliskova J. Estradiol reduces seizures-induced hip-
pocampal injury in ovariectomized female but not in male rats. Neurosci Lett
2003;342:201–5.
Glien M, Brandt C, Potschka H, Lo¨scher W. Effects of the novel antiepileptic drug
levetiracetam on spontaneous recurrent seizures in the rat pilocarpinemodel of
temporal lobe epilepsy. Epilepsia 2002;43:350–7.
Glien M, Brandt C, Potschka H, Voigt H, Ebert U, Lo¨scher W. Repeated low-dose
treatment of rats with pilocarpine: low mortality but high proportion of rats
developed epilepsy. Epilepsy Res 2001;46:111–9.
Gofﬁn K, Nissinen J, Van Laere K, Pitka¨nen A. Cyclicity of spontaneous recurrent
seizures in pilocarpine model of temporal lobe epilepsy in rat. Exp Neurol
2007;205:501–5.
Gombos Z, Spiller A, Cottrell GA, Racine RJ, McIntyre Burnham W. Mossy ﬁber
sprouting induced by repeated electroconvulsive shock seizures. Brain Res
1999;844:28–33.
GunnarMR, Donzella B. Social regulation of the cortisol levels in early human devel-
opment. Psychoneuroendocrinology 2002;27:199–220.
Hamani C, Mello LE. Status epilepticus induced by pilocarpine and picrotoxin.
Epilepsy Res 1997;28:73–82.
Hamani C, Mello LE. Spontaneous recurrent seizures and neurophatology in the
chronic phase of the pilocarpine and picrotoxin model epilepsy. Neurol Res
2002;24:199–209.
Hamilton SE, Loose MD, Qi M, Levey AI, Hille B, McKnight GS, et al. Disruption of the
m1 receptor gene ablates muscarinic receptor-dependent M current regulation
and seizure activity in mice. Proc Natl Acad Sci USA 1997;94:13311–6.
Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contri-
butions of population-based studies from Rochester, Minnesota. Mayo Clin Proc
1996;71:576–86.
Hirsch E, Baram TZ, Snead III OC. Ontogenic study of lithium-pilocarpine-induced
status epilepticus in rats. Brain Res 1992;583:120–6.
Honchar MP, Olney JW, Sherman WR. Systemic cholinergic agents induce seizures
and brain damage in lithium-treated rats. Science 1983;220:323–5.
Hort J, Brozek G, Koma´rek V, Langmeier M, Mares P. Interstrain differences in
cognitive functions in rats in relation to status epilepticus. Behav Brain Res
2000;112:77–83.
Hughes P, Young D, Dragunow M. MK-801 sensitizes rats to pilocarpine
induced limbic seizures and status epilepticus. Neuroreport 1993;4:314–
6.
Jones DM, Esmaeil N, Maren S, Macdonald RL. Characterization of pharmacoresis-
tance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus.
Epilepsy Res 2002;50:301–12.
Jope RS, Morrisett RA, Snead III OC. Characterization of lithium potentia-
tion of pilocarpine-induced status epilepticus in rats. Exp Neurol 1986;91:
471–80.
KlitgaardH,MatagneA, Vanneste-Goemaere J,MargineanuDG. Pilocarpine-induced
epileptogenesis in the rat: impact of initial duration of status epilepti-
cus on electrophysiological and neuropathological alterations. Epilepsy Res
2002;51:93–107.
Knopp A, Kivi A, Wozny C, Heinemann U, Behr J. Cellular and network properties
of the subiculum in the pilocarpine model of temporal lobe epilepsy. J Comp
Neurol 2005;483:476–88.
Kobayashi M, Wen X, Buckmaster PS. Reduced inhibition and increased output of
layer II neurons in the medial entorhinal cortex in a model of temporal lobe
epilepsy. J Neurosci 2003;23:8471–9.
Kubova´ H, Rejchrtova´ J, Redkozubova O, Mares P. Outcome of status epilepticus
in immature rats varies according to the paraldehyde treatment. Epilepsia
2005;46(Suppl 5):38–42.Kumar SS, Buckmaster PS. Hyperexcitability, interneurons, and loss of GABAergic
synapses in entorhinal cortex in a model of temporal lobe epilepsy. Neurobiol
Dis 2006;26:4613–23.
Kwak SE, Kim JE, Kim DS, Won MH, Lee HJ, Choi SY, et al. Differential paired-pulse
responses between the CA1 region and the dentate gyrus are related to altered
CLC-2 immunoreactivity in the pilocarpine-induced rat epilepsy model. Brain
Res 2006;1115:162–8.
Lai MC, Holmes GL, Lee KH, Yang SN, Wang CA, Wu CL, et al. Effect of neonatal isola-
tion on outcome following neonatal seizures in rats—the role of corticosterone.
Epilepsy Res 2006;68:123–36.
Lehmann TN, Gabriel S, Eilers A, Njunting M, Kovacs R, Schulze K, et al. Fluores-
cent tracer in pilocarpine-treated rats showswidespread aberrant hippocampal
neuronal connectivity. Eur J Neurosci 2001;14:83–95.
Leite JP, Bortolotto ZA, Cavalheiro EA. Spontaneous recurrent seizures in rats: an
experimental model of partial epilepsy. Neurosci Biobehav Rev 1990;14:511–7.
Leite JP, Cavalheiro EA. Effects of conventional antiepileptic drugs in a model of
spontaneous recurrent seizures in rats. Epilepsy Res 1995;20:93–104.
Leite JP, Garcia-Cairasco N, Cavalheiro EA. New insights from the use of pilocarpine
and kainate models. Epilepsy Res 2002;50:93–103.
Lemos T, Cavalheiro EA. Suppression of pilocarpine-induced status epilepticus and
the late development of epilepsy in rats. Exp Brain Res 1995;102:423–8.
Liu Z, Gatt A, Werner SJ, Mikati MA, Holmes GL. Long-term behavioral deﬁcits fol-
lowing pilocarpine seizures in immature rats. Epilepsy Res 1994a;19:191–204.
Liu Z, Nagao T, Desjardins GC, Gloor P, Avoli M. Quantitative evaluation of neu-
ronal loss in thedorsal hippocampus in ratswith long-termpilocarpine seizures.
Epilepsy Res 1994b;17:237–47.
Longo D. Characterization of pharmacoresistance in a model of temporal lobe
epilepsy, Thesis. Modena: University of Modena and Reggio Emilia, 2005, p. 74.
sciencG. Curia et al. / Journal of Neuro
LongoBM,Mello LE. Blockadeof pilocarpine- or kainate-inducedmossyﬁber sprout-
ing by cycloheximide does not prevent subsequent epileptogenesis in rats.
Neurosci Lett 1997;226:163–6.
Longo BM, Sanabria ER, Gabriel S, Mello LE. Electrophysiologic abnormalities of the
hippocampus in the pilocarpine/cycloheximide model of chronic spontaneous
seizures. Epilepsia 2002;43(Suppl 5):203–8.
Loscher W. Animal models of epilepsy for the development of antiepileptogenic
and disease-modifying drugs. A comparison of the pharmacology of kindling
and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res
2002;50:105–23.
Marchi N, Oby E, Batra A, Uva L, De Curtis M, Hernandez N, et al. In vivo and in vitro
effects of pilocarpine: relevance to ictogenesis. Epilepsia 2007;48:1934–46.
MathernGW,Adelson PD, Cahan LD, Leite JP. Hippocampal neurondamage in human
epilepsy: Meyer’s hypothesis revisited. Prog Brain Res 2002;135:237–51.
Mathern GW, Babb TL, Armstrong DL. Hippocampal sclerosis. In: Engel J, Pedley TA,
editors. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven;
1997a. p. 133–55.
Mathern GW, Kuhlman PA, Mendoza D, Pretorius JK. Human fascia dentata anatomy
and hippocampal neuron densities differ depending on the epileptic syndrome
and age at ﬁrst seizure. J Neuropathol Exp Neurol 1997b;56:199–212.
Mejı`as-Aponte CA, Jime´nez-Rivera CA, Segarra AC. Sex differences inmodels of tem-
poral lobe epilepsy: role of testosterone. Brain Res 2002;944:210–8.
Mello LE, Covolan L. Spontaneous seizures preferentially injure interneurons in the
pilocarpinemodelof chronic spontaneous seizures. EpilepsyRes1996;26:123–9.
Morimoto K, Fahnestock M, Racine RJ. Kindling and status epilepticus models of
epilepsy: rewiring the brain. Prog Neurobiol 2004;73:1–60.
Morrisett RA, JopeRS, Snead IIIOC. Effects of drugson the initiationandmaintenance
of status epilepticus induced by administration of pilocarpine to lithium-
pretreated rats. Exp Neurol 1987;97:193–200.
Nagao T, Alonso A, Avoli M. Epileptiform activity induced by pilocarpine in the rat
hippocampal-entorhinal slice preparation. Neuroscience 1996;72:399–408.
Olney JW, de Gubareff T, Labruyere J. Seizure-related brain damage induced by
cholinergic agents. Nature 1983;301:520–2.
Patel S, Meldrum BS, Fine A. Susceptibility to pilocarpine-induced seizures in rats
increases with age. Behav Brain Res 1988;31:165–7.
Pitka¨nen A, Schwartzkroin PA, Moshe´ SM. Models of seizures and epilepsy. Burling-
ton: Elsevier Academic Press; 2006. p. 712.
Pitka¨nen A, Sutula TP. Is epilepsy a progressive disorder? Prospects for new thera-
peutic approaches in temporal-lobe epilepsy. Lancet Neurol 2002;1:173–81.
Poirier JL, CapekR,DeKoninckY.Differential progressionofDarkNeuron and Fluoro-
Jade labelling in the rat hippocampus following pilocarpine-induced status
epilepticus. Neuroscience 2000;97:59–68.
Poulsen FR, Jahnsen H, Blaabjerg M, Zimmer J. Pilocarpine-induced seizure-like
activity with increased BNDF and neuropeptide Y expression in organotypic
hippocampal slice cultures. Brain Res 2002;950:103–18.
Priel MR, Albuquerque EX. Short-term effect of pilocarpine on rat hippocampal
neurons in culture. Epilepsia 2002;43(Suppl 5):40–6.
Priel MR, dos Santos NF, Cavalheiro EA. Developmental aspects of the pilocarpine
model of epilepsy. Epilepsy Res 1996;26:115–21.
Purpura DP, Penry JK, Woodbury DM, Tower DB, Walter RD. Experimental models of
epilepsy—a manual for the laboratory worker. New York: Raven Press; 1972. p.
650.
Racine RJ. Modiﬁcation of seizure activity by electrical stimulation. II. Motor seizure.
Electroenceph Clin Neurophysiol 1972;32:281–94.Raspall-Chaure M, Chin RF, Neville BG, Bedford H, Scott RC. The epidemiol-
ogy of convulsive status epilepticus in children: a critical review. Epilepsia
2007;48:1652–63.
Russell RW. Extrapolation from animals to man. In: Streinberg H, editor. Animal
behavior and drug action. London: Churchill; 1964. p. 410–8.
Sanabria ERG, da Silva AV, Spreaﬁco R, Cavalheiro EA. Damage, reorganization, and
abnormal neocortical hyperexcitability in the pilocarpine model of temporal
lobe epilepsy. Epilepsia 2002;43(Suppl 5):96–106.
Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disor-
ders. Arch Gen Psychiat 2000;57:925–35.
Sapolsky RM, Meaney MJ. Maturation of the adrenocortical stress response: neu-
roendocrine control mechanisms and the stress hyporesponsive period. Brain
Res 1986;396:64–76.
ScharfmanHE, SmithKL, Goodman JH, Sollas AL. Survival of dentate hilarmossy cells
after pilocarpine-induced seizures and their synchronizedburst dischargeswith
area CA3 pyramidal cells. Neuroscience 2001;3:741–59.
Scharfman HE, Sollas AE, Berger RE, Goodman JH, Perce JP. Perforant path activa-
tion of ectopic granule cells that are born after pilocarpine-induced seizures.
Neuroscience 2003;121:1017–29.
Schwartzkroin PA. Epilepsy: models mechanisms and concepts. Cambridge Univer-
sity Press; 1983. p. 558.
Shibley H, Smith BN. Pilocarpine-induced status epilepticus results in mossy ﬁber
sprouting and spontaneous seizures in C57BL/6 and CD-1 mice. Epilepsy Res
2002;49:109–20.
Silva AV, Sanabria ERG, Cavalheiro EA, Spreaﬁco R. Alterations of the neocortical
GABAergic system in the pilocarpinemodel of temporal lobe epilepsy: neuronal
damage and immunocytochemical changes in chronic epileptic rats. Brain Res
Bull 2002;58:417–21.e Methods 172 (2008) 143–157 157
Sloviter RS. The neurobiology of temporal lobe epilepsy: too much information, not
enough knowledge. C R Biol 2005;328:143–53.
Sloviter RS, Zappone CA, Bumanglag AV, Norwood B, Kudrimoti H. On the rele-
vance of prolonged convulsive status epilepticus in animals to the etiology and
neurobiology of human temporal lobe epilepsy. Epilepsia 2007;48(Suppl 8):
6–10.
Smith-Swintosky VL, Pettigrew LC, Sapolsky RM, Phares C, Craddock SD, Brooke SM,
et al.Metyrapone, an inhibitor of glucocorticoidproduction, reduces brain injury
induced by focal and global ischemia and seizures. J Cereb Blood Flow Metab
1996;16:585–98.
Smolders I, Khan GM, Manil J, Ebinger G, Michotte Y. NMDA receptor-mediated
pilocarpine-induced seizures: characterization in freely moving rats by micro-
dialysis. Br J Pharmacol 1997;121:1171–9.
Spencer SS.When should temporal-lobe epilepsy be treated surgically? Lancet Neu-
rol 2002;1:375–82.
Starr MS, Starr BS. Paradoxical facilitation of pilocarpine-induced seizures in the
mouse by MK-801 and the nitric oxide synthesis inhibitor L-NAME. Pharmacol
Biochem Behav 1993;45:321–5.
Thompson K, Wasterlain C. Lithium-pilocarpine status epilepticus in the immature
rabbit. Dev Brain Res 1997;100:1–4.
ThompsonSE,WoodhallGL, JonesRSG.Depressionof glutamate andGABAreleaseby
presynaptic GABAB receptors in the entorhinal cortex in normal and chronically
epileptic rats. Neurosignals 2007;15:202–16.
Towﬁghi J, Housmana C, Brucklacherb R, Vannucci RC. Neuropathology of seizures
in the immature rabbit. Dev Brain Res 2004;152:143–52.
Turski WA, Cavalheiro EA, Bortolotto ZA, Mello LM, Schwarz M, Turski L. Seizures
produced by pilocarpine in mice: a behavioral, electroencephalographic and
morphological analysis. Brain Res 1984;32:237–53.
Turski WA, Cavalheiro EA, Schwarz M, Czuczwar SLJ, Kleinrok Z, Turski L.
Limbic seizures produced by pilocarpine I rats: behavioral, electroen-
cephalographic and neuropathological study. Behav Brain Res 1983a;9:
315–35.
TurskiWA, Czuczwar SJ, Kleinrok Z, Turski L. Cholinomimetics produce seizures and
brain damage in rats. Experientia 1983b;39:1408–11.
Turski L, Ikonomidou C, Turski WA, Bortolotto ZA, Cavalheiro EA. Review:
cholinergic mechanisms and epileptogenesis. The seizures induced by pilo-
carpine: a novel experimental model of intractable epilepsy. Synapse 1989;3:
154–71.
Uva L, Librizzi L, Marchi N, Noe F, Bongiovanni R, Vezzani A, et al. Acute induc-
tion of epileptiform discharges by pilocarpine in the in vitro isolated guinea-pig
brain requires enhancement of blood-brain barrier permeability. Neuroscience
2008;151:303–12.
Valente SG, Naffah-Mazzacoratti MG, Pereira Jr M, Silva I, Santos NF, Bracat EC, et al.
Castration in female rats modiﬁes the development of the pilocarpine model of
epilepsy. Epilepsy Res 2002;49:181–8.
Van der Linden S, Panzica F, de Curtis M. Carbachol induces fast oscillations in the
medial but not in the lateral enthorinal cortex of the isolated guinea pig brain. J
Neurophysiol 1999;82:2441–50.
van Vliet EA, da Costa Arau´jo S, Redeker S, van Schaik R, Aronica E, Gorter JA. Blood-
brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain
2007;130:521–34.
Vazquez DM. Stress and the developing limbic-hypothalamic pituitary-adrenal axis.
Psychoneuroendocrinology 1998;23:663–700.
Veliskova J. Behavioral characterization of seizures in rats. In: Pitka¨nen A,
Schwartzkroin PA, Moshe´ SL, editors. Models of seizures and epilepsy. Burling-
ton: Elsevier Academic Press; 2006. p. 601–11.
Volk HA, Arabadzisz D, Fritschy JM, Brandt C, Bethmann K, Lo¨scher W. Antiepileptic
drug-resistant rats differ from drug-responsive rats in hippocampal neurode-
generation and GABAA receptor ligand binding in a model of temporal lobe
epilepsy. Neurobiol Dis 2006;21:633–46.
Wada A, Yokoo H, Yanagita T, Kobayashi H. Lithium: potential therapeutics against
acute brain injuries and chronic neurodegenerative disease. J Pharmacol Sci
2005;99:307–21.
Wieser HG. ILAE Commission on Neurosurgery of Epilepsy. ILAE Commission
Report. Mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia
2004;45:695–714.
Williams PA, Wuarin JP, Dou P, Ferraro DJ, Dudek FE. Reassessment of the
effects of cycloheximide on mossy ﬁber sprouting and epileptogenesis in
the pilocarpine model of temporal lobe epilepsy. J Neurophysiol 2002;88:
2075–87.
WinawerMR,Makarenko N,McCloskey DP, Hintz TM, Nair N, Palmer AA, et al. Acute
and chronic responses to the convulsant pilocarpine in DBA/2J and A/J mice.
Neuroscience 2007;149:465–75.
Wozny C, Gabriel S, Jandova K, Schulze K, Heinemann U, Behr J. Entorhinal cortex
entrains epileptiform activity in CA1 in pilocarpine-treated rats. Neurobiol Dis
2005;19:451–60.
Yang J, Woodhall GL, Jones RSG. Tonic facilitation of glutamate release by presynap-
tic NR2B-containing NMDA receptors is increased in the entorhinal cortex of
chronically epileptic rats. J Neurosci 2006;26:406–10.
Zhang X, Cui SS, Wallace AE, Hannesson DK, Schmued LC, Saucier DM, et al.
Relations between brain pathology and temporal lobe epilepsy. J Neurosci
2002;22:6052–61.
